	Termamyl

Parameter	Model (5) versus model (1)	Model (6) versus model (1)	Model (7) versus model (1)

vmax	t value = −2.874	t value = −3.214	t value = −3.327

P value = 0.045*	P value = 0.032*	P value = 0.029*

D.F. = 4	D.F. = 4	D.F. = 4

KM	t value = −1.921	t value = −1.873	t value = −1.683

P value = 0.127	P value = 0.134	P value = 0.168

D.F. = 4	D.F. = 4	D.F. = 4

	San Super

Parameter	Model (5) versus model (1)	Model (6) versus model (1)	Model (7) versus model (1)

vmax	t value = −2.582	t value = −2.053	t value = −3.179

P value = 0.061	P value = 0.109	P value = 0.033*

D.F. = 4	D.F. = 4	D.F. = 4

KM	t value = −1.982	t value = −1.895	t value = −1.778

P value = 0.118	P value = 0.131	P value = 0.150

D.F. = 4	D.F. = 4	D.F. = 4

	BAN

Parameter	Model (5) versus model (1)	Model (6) versus model (1)	Model (7) versus model (1)

vmax	t value = −2.301	t value = −2.182	t value = −2.089

P value = 0.083	P value = 0.094	P value = 0.105

D.F. = 4	D.F. = 4	D.F. = 4

KM	t value = −0.689	t value = −0.638	t value = −0.577

P value = 0.529	P value = 0.558	P value = 0.595

D.F. = 4	D.F. = 4	D.F. = 4


Health Care Providers

Unqualified providers (UQP)	Yes	Qualified Providers (QP)	Yes

n*	%	n	%

Village doctor	416	92.7	Public

Drug stores	341	75.9	Upazila Health Complex	136	30.3

Self-medication	302	67.3	Union Health/Satellite Clinic	100	22.3

FWA/FWV/Nurses	161	35.9	Private

Medical assistant	39	8.7	Private clinic	160	35.5

Homeopath	158	35.2	Paramedics	266	59.1

Spiritual treatment	94	20.9

Folk medicine	142	31.6

*n=number


	No CAD (%) (n = 15)	CAD (%) (n = 38)

Hypertension (blood pressure > 140/90 mmHg or on antihypertensive therapy)	60	97

Increased abdominal circumference (male > 92 cm, females > 88 cm)	33.3	79.1

Abnormal glucose tolerance	0	55.26

Raised triglycerides (> 1.7 mmol/l)	26.7	50

Low HDL cholesterol (men < 1.0 mmol/l, women < 1.3 mmol/l)	33.33	42.10

Raised LDL cholesterol (> 3 mmol/l)	13.33	42.10

Cigarette smoking/previous smokers	20	62.5

Mean CIMT (mm)	0.998	1.13

Increased CIMT (> 0.8 mm)	53	76


(N = 24)	 Distance from the bladder neck	Distance from the echolucent urethral lumen

 	[mm]	% of urethral length	[mm]

Mean	19.43	64.9%	3.13

Median	19.00	64.5%	3.30

Std. dev.	3.19	6.9%	0.94


	Response options for doctors and researchersb

Benefit				Harm

A great deal	Quite a lot	Only a little	No benefit or harm	Only a little	Quite a lot	A great deal

Criteria for doctors and researchers

1. Significant discussiona or other intervention that presumably reduces other health care use	x

2. Need to contact child welfare	x

3. Some referrals to secondary care	x	x

4. Doctor’s role irreplaceable by nurse		x

5. Presumably reduced concernb		x

6. Some significant discussionsb		x

7. Nurse could have replaced the doctor			x

8. No significant harm as consequence of unhandled concerns			x

9. Suspicion that interaction failed or suspicion of no progress in care					x

10. The interaction failed or here was no progress in care						x

11. Suspicion of negative PREM or refusal of school doctor services in the future and no progress in care							x

PREM question

How much benefit or harm did you perceive from the school doctor’s health check?								I don’t know

Response options for parents	x	x	x	x	x	x	x	x

Response options for children		x	x	x	x	x


Source	A lot	A fair amount	A little	Almost none

Chicago City Health Department	9.5	21.4	33.3	35.7

Chicago Housing Authority	9.5	14.3	23.8	52.4

Doctor	19.1	14.3	21.4	45.2

Friends and relatives	31.0	14.3	28.6	26.2

Illinois Department of Health	16.7	19.1	21.4	42.9

Newspaper	21.4	21.4	40.5	16.7

People for Community Recovery (PCR)	45.2	21.4	21.4	11.9

Private industry, such as Waste Management or Ford Motor Company	9.5	7.1	19.1	64.3

Radio	21.4	14.3	21.4	42.9

Television	31.0	28.6	33.3	7.1

U.S. Environmental Protection Agency	-	40.5	28.6	30.9

University/College scientists	4.8	26.2	33.3	35.7


Appendix I: Key Economic Variables		Reference/Data Source

ECONOMIC

Annual Discount Rate	3%	27

Exchange Rate: Shekels to USD (2005)	4.35	12

Per capita GDP (USD 2003)	$16,497	12

Training Staff

Number of Clinics in Israel	3000	MOH Statistical Dept.

Staff per clinic receiving training	2	Ashkelon Project

Full Days Training in initial year	2	Ashkelon Project

Days training in subsequent years	1	Ashkelon Project

Cost per ticipant-day of training course	$100	Ashkelon Project

Tele-management & Operational costs per patient.	$60	Ashkelon Project

Nurse/GP guidance per patient in first year of program	$230	Ashkelon Project

Unit Care Costs

Ambulatory visit to Nurse or Nutritionist	$7.83	15 mins visit & 5 mins secretarial time

Ambulatory GP visit	$11.37	15 mins GP & 5 mins secretarial time

Cost of OPV	$99.14	25% of general hospital cost (30)

General Hospital Cost per day	$397	30

ICU cost per day	$1,586	estimated as four times general per diem cost (30)

Rehabilitation Hospital Cost per day	$238.85	30

Home Physiotherapy Visit	$38.53	30

Devices and Procedure costs

Stent	$202	Barzelai Hospital Accounts Dept.

Cypher	$2,989	Barzelai Hospital Accounts Dept.

Diagnostic Catheterisation	$2,464	30

Restenosis	$9,701	30, includes 1 day in ICU & 3 days in cardiac ward

Average cost of Catheterisation with Stent or cypher	$6,925	30

CABG operation	$12,740	30

TPA	$1,800	30 estimated as four times general per diem cost

PRS Streptokinaise	$81	31

Kidney Transplant Cost	$39,132	30

Haemodialysis cost	$313	30

Peritonea dialysis cost	$136	30

% receiving haemodialysis	88.8%	20

Average annual Dialysis Cost	$46,041	30

Drug Costs

Post-MI or stroke drugs per day per patient- Males	$1.92	14

Post-MI or stroke drugs per day per patient- Females	$1.79	14

Post-UAP drugs per day per patient- Males	$1.92	14

Post-UAP drugs per day per patient- Females	$1.79	14

Correct preventive medication per day	$0.92	14, Ace inhibitor, Aspirin & Statin

Inadequate preventive medication per day	$0.31	14, Assumed only 1 correct drug taken


First author (public year) [Reference]	Experimental animal	Inoculum spores	Inoculation route	Outcome	Results

Kawai (2012) [2]	4-5-d old ddY mouse	Kudoa septempunctata	Oral	Bowel movements and FAR	Showing diarrheagenic activity (11/17) and significantly higher FAR

Ahn (2015) [6]	6-wk old BALB/c mice	Kudoa septempunc-tata	Oral	Bowl movements and histo-pathological examination	No significant diarrhea (0/32) and histopathologic changes (0/24)

Jang (2016) [7]	4-5-d old ddY mouse	Kudoa septempunc-tata	Oral	Bowel movements and FAR	No watery stool form (0/20) and no significant variations in FAR

Guo (2015) [8]	4-5-d old BALB/c suckling mice	Myxobolus hongh-uensis	Oral	Bowel movements, FAR, and histopathology	No significant change of FAR, no abnormal stool form (0/25) and no evidence of inflammation (0/25)


MIGS ID	Property	Term

MIGS-31	Finishing quality	High quality draft

MIGS-28	Libraries used	IonTorrent 100 bp and 400 bp single end reads

MIGS-29	Sequencing platforms	IonTorrent PGM

MIGS-31.2	Fold coverage	110×

MIGS-30	Assemblers	Newbler 2.6, MIRA 3.9.18, Sequencher 5.0.1

MIGS-32	Gene calling method	Prodigal

 	Locus Tag	M670

 	Genbank ID	JJRY00000000

 	Genbank Date of Release	2014-06-16

 	GOLD ID	Gi0050495

 	BIOPROJECT	PRJNA209301

 	Project relevance	Environmental, co-denitrification

MIGS 13	Source Material Identifier	LMG 28302


Clinicopathological features	GPx3 expression level (n)

Number	Down regulated	Non-down regulated	P

Sex				0.210

 Male	92	43	49

 Female	21	13	8

Age				0.926

 Younger than 55	57	28	29

 Older than 55	56	28	28

pTNM stagea				0.024 *

 Early stage (1-2)	29	9	20

 Advanced stage (3-4)	83	46	37

Venous infiltration				0.043 *

 Absent	47	18	29

 Present	66	38	28

Tumor sizea				0.462

 Less than 5 cm	47	25	22

 More than 5 cm	65	30	35

Tumor Nodulesa				0.448

 Less than 3	83	39	44

 More than 3	29	16	13

HBsAg				0.794

 Negative	13	6	7

 Positive	100	50	50

AFP levela				0.006 *

 Lower than 20 ng/mL	45	15	30

 Higher than 20 ng/mL	67	40	27

One year recurrencea				0.038*

 Recurrence	42	27	15

 Non-recurrence	62	27	35

Five year recurrencea				0.019*

 Recurrence	62	36	26

 Non-recurrence	43	15	28


Medicine	MIC (mg/L)

AMPH-B	0.5

5-FC	<=0.12

MCZ	0.12

FLCZ	0.25

ITCZ	0.06

MCFG	0.12

VRCZ	<=0.015


Population	Frequency (%)	Number of subjects	Reference

African American	20	50	[48]

African American	36	85	[49]

African American	34	93	[152]

Tanzanians	36	95	[153]

Malawians	∧31 (15)	26	[60]

Ghanaians	46	42	[152]

Ghanaians	25	800	[78]

Ethiopians	∧45.5 (8.7)	262	[45]

Ivory coast	38	41	[152]

Sierra Leone	36	52	[152]

Senegal	60	10	[152]

Guinea	48	21	[152]

West Africa	42	166	[152]

West Africa	50	153	[49]

Yoruba (Ibadan, Nigeria)	35	78	[49]

South Africa	∧41 (23)	80	[154]

Xhosa (South Africa)	∧∧17	109	[155]

CMA (South Africa)	∧∧9	67	[155]

Botswana	36.6	101	[156]

Zimbabwe	49	71	[76]

Uganda	35.6	121	[63]

Uganda	29	7 males	[13]

Mozambique	7	78	[14]


Cultivar	TDZ/BA concentration	No. of explants	% of explants producing massive shoots/budsx(mean ± standard error)

Accent Red	1 μM TDZ + 0 μM BA (IM1)	121	20.5 ± 6.4 A

	2.3 μM TDZ + 1.8 μM BA (IM2)	121	66.5 ± 6.4 B

	1 μM TDZ + 2.2 μM BA (IM3)	119	42.6 ± 6.4 C

Salmon	1 μM TDZ + 0 μM BA (IM1)	65	59.5 ± 5.3 A

Picote	2.3 μM TDZ + 1.8 μM BA (IM2)	68	80.1 ± 4.6 B

	1 μM TDZ + 2.2 μM BA (IM3)	65	43.9 ± 5.3 A


The Value of L (mm)	Strength of the Alternating Magnetic Field (A/m)	Compensation Ratio of Vpp	fL (kHz)	fn(kHz)	Relative Tolerance

20	6892	1.11	-	172	-

25	7299	1.05	160	138	13.7%

30	7499	1.02	140	115	17.8%

40	7651	1	100	86	14%


Manner of intent a,b	Total N (%)	Mean	Std. Dev.	Min	Max

Total firearm deaths	5,660 (100)	138.1	43.5	67	243

 Accidental	164 (2.9)	4	3.2	-	11

 Suicide a	5,025 (88.8)	122.6	40	57	212

 Homicide a	432 (7.6)	10.5	4.7	2	24

 Event of undetermined intent a	34 (0.6)	0.8	0.9	-	3

 Legal investigation.	- (-)	-	-	-	-

 Operation of war c	5 (0.1)	0.1	0.3	-	1

MALE

Total firearm deaths	5,334 (100)	130.1	40.2	64	221

 Accidental	158 (3.0)	3.9	3.1	-	11

 Suicide a	4,863 (91.2)	118.6	37.9	54	199

 Homicide a	276 (5,2)	6.7	3.6	1	15

 Event of undetermined intent a	32 (0.6)	0.8	0.9	-	3

 Legal investigation	- (-)	-	-	-	-

 Operation of war c	5 (0.1)	0.1	0.3	-	1

FEMALE

Total firearm deaths	326 (100)	8	4.1	1	22

 Accidental	6 (1.8)	0.2	0.4	-	1

 Suicide a	162 (49.7)	4	2.7	-	13

 Homicide a	156 (47.9)	3.8	2.3	-	10

 Event of undetermined intent a	2 (0.6)	0.1	0.2	-	1

 Legal investigation	- (-)	-	-	-	-

 Operation of war c	- (-)	-	-	-	-


Gene Description	Unigene	Gene Bank	Function

Cadherin 5, type 2, VE-cadherin	Hs.76206	NM_001795	Plays an important role in cell adhesion and is crucial for vessel growth and maturation.

Collagen, type XVIII, alpha 1	Hs.517356	NM_030582	Component of extra-cellular matrix (ECM) that is important for tissue organization.

Collagen, type IV, alpha 3	Hs.570065	NM_000091

Integrin, alpha V	Hs.436873	NM_002210	Cell adhesion molecules that plays a key role in tumor growth, angiogenesis and metastasis.

Integrin, beta 3	Hs.218040	NM_000212

Hepatocyte growth factor	Hs.396530	NM_000601	Stimulates tumor cell motility, invasion and angiogenesis and its receptor is a tyrosine kinase encoded by c-met.

Ephrin-A3	Hs.516656	NM_004952	Ephrins are cell-membrane-bound ligands for Eph receptor tyrosine kinases and regulate a variety of developmental processes.

Platelet-derived growth factor alpha polypeptide	Hs.645488	NM_002607	Stimulates endothelial cell proliferation.

Epidermal growth factor	Hs.419815	NM_001963	An EGFR ligand, regulates cell growth, proliferation and differentiation.

Neuropilin 2	Hs.471200	NM_003872	Receptor for VEGF and semaphorin (SEMA) and is involved in angiogenesis and neuronal guidance.

Ephrin-B2	Hs.149239	NM_004093	An Eph ligand, promotes cell attachment, cell-adhesion, migration, capillary tube formation and tumor angiogenesis.

Jagged 1	Hs.224012	NM_000214	A notch ligand, it regulates a transmembrane ligand-receptor signaling pathway involved in the regulation of endothelial cell differentiation.

Tumor necrosis factor, alpha-induced protein 2	Hs.525607	NM_006291	A cytokine mainly produced by macrophages causes apoptotic cell death, cellular proliferation, differentiation and inflammation.

TEK tyrosine kinase, endothelial	Hs.89640	NM_000459	Helps in vascular maturation, maintenance of integrity and remodeling.

Transforming growth factor, alpha	Hs.170009	NM_003236	Binds to EGFR and is involved in tumorigenesis.

Vascular endothelial growth factor C	Hs.435215	NM_005429	Involved in angiogenesis and lymphangiogenesis.


Original data	Secret data	XOR result

0	0	0

0	1	1

1	0	1

1	1	0


Studies	BCC +	SCC + (control)

Karahan, et al. [16]	20/20	0/20

Fan, et al. [28]	51/51	-

Krahl & Sellheyer [29]	28/28	-

Ishida, et al. [30]	20/20	-

Filho, et al. [31]	20/20	-

Mashhood, et al. [32]	29/29	0/11

Tan & Sunjaya [9]	23/23	-

Kirzhner & Jakobiec [33]	13/13	-

Dasgeb, et al. [24]	24/24	1/11 (weak positive)

Patil, et al. [12]	9/9	-

Sellheyer, et al. [34]	17/17	0/75

Ansai, et al. [35]	30/31	-

BerEP4 positive	284	1

Ber EP4 negative	1	116

Total	285	117

Sensitivity	284/285 × 100 = 99.6%

Specificity	116/117 × 100 = 99.2%

Positive predictive value	284/285 × 100 = 99.6%

Negative predictive value	116/117 × 100 = 99.1%


Code	Name	Classification algorithm(s) used

CAS	Chinese Academy of Sciences	Naïve Bayes, Support Vector Machine

CBC	CapitalBio Corporation, China	k-Nearest Neighbor, Support Vector Machine

Cornell	Weill Medical College of Cornell University	Support Vector Machine

FBK	Fondazione Bruno Kessler, Italy	Discriminant Analysis, Support Vector Machine

GeneGo	GeneGo, Inc.	Discriminant Analysis, Random Forest

GHI	Golden Helix, Inc.	Classification Tree

GSK	GlaxoSmithKline	Naïve Bayes

NCTR	National Center for Toxicological Research, FDA	k-Nearest Neighbor, Naïve Bayes, Support VectorMachine

NWU	Northwestern University	k-Nearest Neighbor, Classification Tree, Support VectorMachine

SAI	Systems Analytics, Inc.	Discriminant Analysis, k-Nearest Neighbor, Machine Learning,Support Vector Machine, Logistic Regression

SAS	SAS Institute, Inc.	Classification Tree, Discriminant Analysis, LogisticRegression, Partial Least Squares, Support VectorMachine

Tsinghua	Tsinghua University, China	Classification Tree, k-Nearest Neighbor, Recursive FeatureElimination, Support Vector Machine

UIUC	University of Illinois, Urbana-Champaign	Classification Tree, k-Nearest Neighbor, Naïve Bayes,Support Vector Machine

USM	University of Southern Mississippi	Artificial Neural Network, Naïve Bayes, SequentialMinimal Optimization, Support Vector Machine

ZJU	Zejiang University, China	k-Nearest Neighbor, Nearest Centroid


	Not at all	A little bit	Moderately	Quite a bit	Extremely	No/inappropriate answer	Total

	n	%	n	%	n	%	n	%	n	%	n	%	n	%

Any reminder brought back feelings about it	63	21.6	117	40.1	63	21.6	25	8.6	15	5.1	9	3.1	292	100

I had trouble staying asleep	206	70.5	37	12.7	28	9.6	8	2.7	1	0.3	12	4.1	292	100

Other things kept making me think about it	189	64.7	58	19.9	24	8.2	6	2.1	6	2.1	9	3.1	292	100

I felt irritable and angry	234	80.1	38	13.0	7	2.4	4	1.4	0	0.0	9	3.1	292	100

I avoided letting myself get upset when I thought about it or was reminded of it	145	49.7	91	31.2	24	8.2	17	5.8	5	1.7	10	3.4	292	100

I thought about it when I didn't mean to	133	45.5	100	34.2	31	10.6	14	4.8	3	1.0	11	3.8	292	100

I felt as if it hadn't happened or wasn't real	199	68.2	46	15.8	21	7.2	5	1.7	1	0.3	20	6.8	292	100

I stayed away from reminders about it	197	67.5	53	18.2	15	5.1	7	2.4	3	1.0	17	5.8	292	100

Pictures about it popped into my mind	193	66.1	59	20.2	14	4.8	8	2.7	3	1.0	15	5.1	292	100

I was jumpy and easily startled	172	58.9	63	21.6	24	8.2	11	3.8	9	3.1	13	4.5	292	100

I tried not to think about it	152	52.1	67	22.9	34	11.6	18	6.2	7	2.4	14	4.8	292	100

I was aware that I still had a lot of feelings about it,but I didn't deal with them	165	56.5	62	21.2	26	8.9	17	5.8	6	2.1	16	5.5	292	100

My feelings about it were kind of numb	162	55.5	70	24.0	35	12.0	6	2.1	2	0.7	17	5.8	292	100

I found myself acting or feeling as though I was back at that time	214	73.3	42	14.4	17	5.8	4	1.4	1	0.3	14	4.8	292	100

I had trouble falling asieep	212	72.6	38	13.0	14	4.8	10	3.4	4	1.4	14	4.8	292	100

I had waves of strong feelings about it	192	65.8	53	18.2	22	7.5	9	3.1	5	1.7	11	3.8	292	100

I tried to remove it from my memory	201	68.8	42	14.4	21	7.2	9	3.1	4	1.4	15	5.1	292	100

I had trouble concentrating	226	77.4	40	13.7	9	3.1	3	1.0	1	0.3	13	4.5	292	100

Reminders of it caused me to have physical reactions,such as sweating,trouble breathing,nausea,or a pounding heart	227	77.7	38	13.0	12	4.1	4	1.4	0	0.0	11	3.8	292	100

I had dreams about it	246	84.2	28	9.6	4	1.4	1	0.3	0	0.0	13	4.5	292	100

I felt watchful or on-guard	112	38.4	92	31.5	41	14.0	20	6.8	14	4.8	13	4.5	292	100

I tried not to talk about it	187	64.0	54	18.5	22	7.5	11	3.8	5	1.7	13	4.5	292	100


	Sample 1	Sample 2

Control Slide	41	52

Splashing device	29	34


Groups for Comparions	Dependent Variables	Degrees of freedom	Chi-square	p

Control (n=14)	TBARs (nmol/g)	3	3.87	0.28

STZ (n=12)	SOD (U/mg)	3	6.40	0.09

P+STZ (n=12)	CAT (K/g)	3	5.98	0.11

STZ+P (n=13)	GSH-Px (U/mg)	3	3.46	0.33


Scenario 4 - health, Work Cover & employment data linked by researchers

Consent justifications	No consent justifications

Consent provides protection against potential impact of research (10)a	Acceptable practice because of the benefits (5)

Access to identifiable data by researchers requires consent (9)	The findings are presented in de-identified form (3)

Practical considerations of obtaining consent from thousands (3)

Consent required when researchers do the linkage (7)	Acceptable due to cost and time constraints involved when obtaining consent (2)

Consent is required when other spheres of life (apart from health) are involved (7)	Consent lowers research participation rates (2)

Opt-out consent would result in more participants being involved (6)	Low participation rates impact on quality of research (2)

Consent required because of lack of separation of tasks (4)	The information is already there so it should just be used without consent (2)

People have right to choose (4)

Researchers may disclose information to third party (2)	Researchers are not interested in specific cases (2)

Someone on the research team may know the research participants (2)	Strict measures/guidelines provide protection (2)

To ensure people are not upset/do not object (2)	Getting consent could have detrimental effect on participants (1)

No need for consent if data linkage organisation is trustworthy (1)

Opt-in consent captures the people who really want to participate (2)	Researchers will not use information obtained without consent to harm participants (1)

Having the option to consent is good (2)

Information belongs to people (1)	Provided that the linkage organisation was involved so that tasks are separated (1)

People want to control their information (1)

Researchers using identifiable information without consent is intrusive (1)	Researchers will be dealing with de-identified data eventually (1)

Acceptable depending on study (1)

Consent required when participants are experiencing mental health issues, as they may not welcome people delving into their affairs at that point in their lives (1)	Consent would have been given at data collection point (1)

Information given to WorkCover can be shared with researchers, as it was given confidentially (1)

Consent should be sought for all research (1)	Retrospective use of data does not require consent (1)

Consent should be sought at initial point of data collection (1)	People have inflated view of how interesting they are to others (1)

Collecting this kind of information without consent may not be legal (1)

It is very good to obtain consent if it is simple to do so (1)


Demographic data and diagnoses	IPC + sevoflurane (N = 20)	IPC (N = 20)

Age (years)	68 ± 12	68 ± 11

Height (cm)	170 ± 11	170 ± 8

Weight (kg)	77 ± 17	75 ± 9

Male/female	14/6	13/7

Body-Mass-Index (BMI; kg.m-2)	27 ± 5	26 ± 3

Ankle-Brachial-Index (ABI)*	0.58 ± 0.18	0.56 ± 0.05

Side of surgery (right/left)	13 (65%)/7 (35%)	6 (30%)/14 (70%)

Fontaine grade (I/IIa/IIb/III/IV/V)	0/3/14/1/2 (0%/15%/70%/5%/10%)	0/5/14/0/1 (0%/25%/70%/0%/10%)

Obesity	5 (25%)	1 (5%)

Alcohol abuse	1 (5%)	1 (5%)

History of stroke	4 (20%)	1 (5%)

Diabetes mellitus	6 (30%)	5 (25%)

Hyperlipidaemia	14 (70%)	12 (60%)

Hypertonia	18 (90%)	17 (85%)

Hyperuricaemia	1 (5%)	5 (25%)

Coronary heart disease	9 (45%)	6 (30%)

Renal insufficiency	4 (20%)	1 (5%)

Smoking	9 (45%)	10 (50%)


Characteristics of children	Number of children (%)	Mean per year/per team (min/max)	Median per year/per team (P25/P75)

Age of children

 0–1 y	885 (25%)

 1–10 y	1689 (47%)

 11–20 y	879 (24%)

 > 20 y	116 (3%)	144 (43–240)	144 (103–196)

Total of children: 3607 (100%)

Pathologies

 Haematology/Oncology	1816 (50%)

 Neurology-/Degenerative/Metabolic	989 (27%)

 Other (Neonatology/Gastroenterology/Respiratory)	849 (23%)

	Total: 3654 (100%)

Curative/Palliative Patients

 Curative patients	2540 (70%)	102 (1–181)	105 (82–135)

 Palliative patients	910 (25%)	36 (10–86)	23 (20–58)

 Undefined	157 (5%)

	Total: 3607 (100%)

Referral of new patients

 From originating hospital	1848 (51%)

 External hospital	108 (3%)

Total new patients	2056 (54%)

	Total: 3607 (100%)

Length follow-up (children who died)		226 days/child (1–4612 days)	32 days/child (21–201 days)

< 120 days	272 (64%)

 121–240 days	65 (15%)

 241–400 days	31 (7%)

> 401 days	60 (14%)

	Total: 428 (100%)

Location of death

 Hospital	200 (47%)	8 (2–22)	6 (6–10)

 Home	221 (51%)	9 (1–22)	9 (3–16)

 Others (respite care home, others)	7 (2%)	18 (3–32)	19 (12–26)

	Total: 428 (100%)


Acoustic lens properties

Excitation center frequency [MHz]	100

Max PRF [kHz]	100

Gain [dB]	40

Sampling rate [MSamples/s]	400

Focal resolution [μm]	10

Aperture [μm]	950

Aperture angle [°]	55

Working distance [μm]	900


	N

Treatment interruption for reasons other than PD	5

Death for reason other than GBM	1

No measurable disease at time of randomization	6

No imaging available for central review	4

Total	16


Behaviors	Scores

1	2	3

Target: Cat touches a plastic chopstick or trainer’s finger with its nose	Stretching neck toward target	Purposeful movement towards target, but no touch; or touches with face but not nose	Actual contact with nose

Spin (in either direction): Cat turns body in a circle	Head follows or <90 degree turn	Spins approximately 91–270 degrees	Spins approximately 271–360 degrees

Sit: Cat assumes a sitting position, with hind-end on floor and front paws touching the floor, in a weight-bearing stance	Some hind-end crouching	Hind-end on floor or in close proximity and/or front paws go up	Front paws on floor and hind-end contact with floor

High-five: Cat touches a trainer’s hand with a front paw	Any degree of front paw lift (one or both paws)	Movement towards hand with just one paw	Purposeful hand contact with one paw


	Odds ratio (95 % confidence interval)	P-value

Age	1.0 (0.9–1.1)	0.11

Race

 African American	1.3 (0.6–3.0)	0.47

 Other	1.2 (0.7–2.3)	0.49

At least one previous prostate biopsy	0.7 (0.3–1.3)	0.26

Abnormal Digital Rectal Exam	30.5 (11.8–92.2)	<0.001

Family history of prostate cancer	3.5 (1.8–6.8)	<0.001

Prostate-specific antigen (ng/mL)a	4.4 (3.3–5.9)	<0.001

Sarcosine uM in 20uL seruma	1.1 (0.7–1.8)	0.64


Taxon, area, location	Code	N	Date	Coordinates

Clupea pallasii

NW Pacific & Bering Sea

 Sea of Japan	JAP	24	2005	48.40°N, 141.94°E

 Sea of Okhotsk, Taui Bay	OKH	37	5.2005	59.40°N, 150.12°E

 	 	 	31.8.2007	59.18°N, 149.05°E

 Bering Sea, Togiak Bay	BER	48	 	58°N, 160°W

NE Pacific

 Gulf of Alaska, Kodiak Bay	KOD	27	 	57°N, 154°W

 Washington	WAS	28	2009	48°N, 125°W

Pacific, Total	 	164

Pechora Sea

 Chesha Bay, Yarnei River	CHE	21	16.6.2010	67.78°N, 45.99°E

 Indiga Bay, near Svyatoi Nos	IND	21	20.6.2010	67.87°N, 48.58°E

White Sea

 Mezen Bay, West Kanin	MEZ	24	16.6.2010	67.20 N, 43.49 E

 Dvina Bay, Yandovaya Inlet	YAN	36+5	5.2001; 15.6.2010	64.66°N, 39.82°E

 Onega Bay, Kolezhma Inlet	KLZ	21	11.5.2001	64.30°N, 35.91°E

 Onega Bay, Kii Island	KIY	12	18.5.2001	64.00°N, 37.90°E

 Gulf of Kandalaksha, Chupa Inlet*	CHP	10	19.4.2001	66.30°N, 33.47°E

 Gulf of Kandalaksha, Chupa Inlet	CHU	23	30.8.1994	66.30°N, 33.47°E

 Gulf of Kandalaksha, Kolvitsa*	KOL	38	30.4.2010	67.04°N, 32.55°E

 Gulf of Kandalaksha, Umba	UMB	32	16.6.2010	66.65°N, 34.25°E

Norwegian Sea

 Balsfjord	BLS	39	28.4.2009	69.27°N, 19.28°E

European C. pallasii, Total	 	282

Clupea harengus

 NW Atlantic, Canada	CAN	26	10.3.2010	47°N, 47°E

 Norwegian Sea	NOR	26	2010	72°N, 16°E

 Baltic Sea, Bothnian Sea	BOT	30	2009	62°N, 19°E

Total C. harengus	 	85

Total, both species	 	528


Characteristic	Distribution

Sex [n (%)]

Female	117 (12%)

Male	848 (88%)

Age [mean (range)]	37 (18 – 67)

Transmission Risk Factor [n (%)]

MSM, not IDU	567 (59)

IDU	189 (20)

Heterosexual	160 (17)

Other/Unknown	49 (5)

Race/Ethnicity [n (%)]

Black	139 (14)

Hispanic	193 (20)

White	559 (58)

Other/Unknown	74 (8)

Prior Antiretroviral Treatment [n (%)]

Experienced	571 (59)

Naive	394 (41)

Absolute CD4 [mean (std dev)]	233 (337)

log10 HIV Plasma Viral Load [mean (std dev)]	4.6 (1.7)


Patients	Cancer classification	Clinical stage

1	Adenocarcinoma	cT2N + M0, Stage III

2	Adenocarcinoma	cT3N + M0, Stage III

3	Adenocarcinoma	cT3N + M0, Stage III

4	Adenocarcinoma	cT3N0M0, Stage II

5	Adenocarcinoma	cT3N + M0, Stage III

6	Adenocarcinoma	cT3N + M0, Stage III

7	Adenocarcinoma	cT3N + M0, Stage III


NOPES score	≥1	≥2	≥3

Sensitivity (%)	98.7	68.9	24.3

Specificity (%)	14.1	59.2	95.1

Validity index (%)	38.4	62	74.8

Positive predictive value (%)	31.6	40.5	66.7

Negative predictive value (%)	96.3	82.6	75.8

Youden Index	0.13	0.28	0.19

Prevalence of BE (%)	31.6	40.8	66.7


Plant	Material	Shoot Weight	Lead Concentration	Lead Uptake

(a)	(b)	(c = a × b)

(mg box−1 DW)	(μg g−1 DW)	(μg box−1 DW)

Barley	+HAP	410 ± 90	7 ± 2	2.7 ± 0.2

−HAP	240 ± 40	90 ± 70	18 ± 13

p value		0.1513	0.2964	0.2867

Hairy vetch	+HAP	700 ± 100	9 ± 1	6.1 ± 1.2

−HAP	244 ± 24	24 ± 7	5.5 ± 1.3

p value		0.0014 **	0.1005	0.7530


	Clinical Dosage	Flow Rate	Volume and Syringe Size

Loading Dose	4 g MgSO4 over 20 min	60 mL/h	20 mL in a single 20 mL syringe

Maintenance Dose	1 g/h MgSO4 for 24 h	5 mL/h	120 mL in two 60 mL syringes


	Direct	Indirect

Medical	Medical consultations (Ch-P)c	d

Skills training (Ch)

Parent training (P)

Day-care treatment (Ch)

Hospitalization (Ch)

Medication (Ch-P)

Non-medical	Remedial teaching at school (Ch)	Agency for child welfare (Ch)

Weekend care (Ch)	Police (Ch)

Care after school (Ch)	Special education (Ch)

Diet (Ch)	Productivity losses

	Absenteeism (P)

	Presenteeism (P)


Attributes	Levels

Cervical cancer risk	0, 2, 4 in 1,000

Genital wart risk	0, 50, 100 in 1,000

Common side effect e.g. mild fever, little pain	2, 6, 10, 14 in 100

Costs for 3 doses of HPV vaccinea	0 Baht, 5,000 Baht, 10,000 Baht


Laparoscopic surgery	Preoperative intraabdominal adhesions evaluation scores	Success rate	χ2	P value	RR

LC (n = 118)	≤ 3 points, n = 62	96.8%(60/62)	59.70	0.001	3.38a

>3 points, n = 56	28.6%(16/56)

LCBDE+LC (n = 171)	≤ 3 points, n = 59	84.7%(50/59)	53.41	0.001	3.27b

>3 points, n = 112	25.9%(29/112)


Variable	No. (%)

Age at admission (days)

 21–90	8,168 (42.7)

 91–180	5,819 (30.5)

 181–270	3,196 (16.7)

 271–365	1,926 (10.1)

Gestation (weeks)

 37 1/7–44	16,049 (84.0)

 34 1/7–37	2,035 (10.7)

 29 1/7–34	789 (4.1)

 25–29	236 (1.2)

Sex

 Male	11,277 (59.7)

 Female	7,832 (40.3)

Ethnicity

 Hispanic	12,373 (64.8)

 Non-Hispanic	6,393 (33.5)

 Unknown	343 (1.7)

Recorded respiratory/cardiac conditions of newborn

 Respiratory distress syndrome	609 (3.2)

 Bronchopulmonary dysplasia	85 (0.4)

 Pulmonary anomalies	63 (0.3)

 Any pulmonary disease	678 (3.6)

 Cardiac anomalies	505 (2.6)

Payment source

 MediCal	11,673 (61.1)

 Private insurance/HMO/PPO	6,670 (34.9)

 Other	766 (4.0)


Procedure	Percent Agreeing quite or very important.

ACLS/CPR	91

Central Venous Catheter Insertion	93

Paracentesis	90

Endotracheal Intubation	89

Lumbar Puncture	89

Thoracentesis	87

Arterial access and blood gases	82

Ambulatory ECG	79

Cardioversion	77

Exercise Stress Testing	77

Hemodynamic Monitoring	76

Temporary Pacemaker Insertion	75

Mechanical Ventilation	75

Transthoracic Pacing	71

Arthrocentesis	70

Bone Marrow Aspiration and Biopsy	60

Chest Tube Insertion	58

Venipuncture	50


PATIENT	SIZE AND POSITION OF CHROMOSOME 15 DELETION	ADDITIONAL CHROMOSOME ABERRATION	SEX	CLEFT PALATE	HEART DEFECT	DEVELOPMENTAL DELAY	FACIES ANOMALIES	ADDITIONAL ABNORMALITIES

Present case	del(15)(q14) (submicroscopic, 1,6 Mb)	t(1;13)(p31.1;q13),t(3;19)(p23;p12), t(9;15)(p23;q14),t(14;18)(q22;p11.23)	M	+	-	+	+	-

Chen et al., 2008	del(15)(q14) (submicroscopic, 5,6 Mb)	-	M	+	VSD	+	+	Epilepsy; speech and language disorder

Brunetti-Pierri et al., 2008 case 1	del(15)(q14) (submicroscopic, 4,2 Mb)	-	M	+ (Bifid uvula)	+	+	+	Bilateral inguinal hernias, autistic spectrum behavior

Brunetti-Pierri et al., 2008 case 2	del(15)(q13-q14) (submicroscopic, 8,9 Mb)	-	F	-	+	+	+	Hypotonia,feeding difficulties

Erdogan et al., 2007	del(15)(q14) (submicroscopic, 5,3 Mb)	-	F	+	ASD	+	+	Low-set ears, OFC 3rd percentile

Galan et al., 1991	del(15)(q12-q14)	-	M	+ (Bifid uvula)	Pulmonary valve stenosis	+	+	Right cryptorchidism, hearing deficency

Tonk et al., 1995	del(15)(q12-q14)	-	M	+	VSD, PDA, ischemic cardiomyopathy	+	+	Large fontanelles, hearing deficency

Autio et al., 1988	del(15)(q13-q15)	-	M	+	ASD	+	+	Cryptorchidism, kidney defect, corpus callosum agenesis

Herva and Vuorinen, 1980	del(15)(q12-q14)	Mosaic with 46, XY	M	-	VSD, hypoplastic pulmonary artery, atretic tricuspid valve	Died at 7 days	+	Cryptorchidism

Pauli et al., 1983	del(15)(pter-q15)	del(11)(q25-qter)	M	+ (Bifid uvula)	VSD	+	+	Cryptorchidism, unilateral renal ptosis

Windpassinger et al., 2003	del(15)(pter-q14)	del(3)(qter)	M	-	Persistent foramen ovale, PDA	+	+	Cryptorchidism, clubfeet, strabismus

Kucerova et al., 1979	del(15)(pter-q15)	del(3)(pter-p25)	M	-	-	+	+	Cryptorchidism

Duckett and Roberts, 1981	del(15)(pter-q14or15)	Trisomy 13(pter-q32 or 33)	F	+ (Bifid uvula)	VSD, ASD, PDA, transposition of great vessels	Died at 14 hr	+	Microphthalmia, tracheo-oesophageal fistula

Ming et al., 1977	del(15)(pter-q21)	del(6)(q27-qter)	F	+	-	Died at 3 days	+	Microphthalmia

Schwartz et al., 1985	del(15)(pter-q14)	del(22)(pter-q13.2)	M	-	Coarctation of aorta, PDA	+	+	Cleft alveolar ridge, hydronephrosis

Matsumura et al., 2003	del(15)(pter-q14)	Trisomy 22q	M	-	PDA	+	+	Renal failure, cryptorchidism


Non-financial COI terms	n (%)

Personal relationship	29 (54)

Other	21 (39)

Non-financial COI	18 (33)

Professional	15 (28)

Academic competition	12 (22)

Personal opinion	10 (19)

Academic	9 (17)

Intellectual passion	9 (17)

Religious views	8 (15)

Political	8 (15)

Personal	8 (15)

Intellectual	7 (13)

Ideological	7 (13)

Competing loyalties	5 (9)

Advocacy groups/institutional advocacy	5 (9)

Institutional	3 (6)

Legal relationship	3 (6)

Governmental	1 (2)


Lambertian Scattering	Epidermis	Dermis	Veins	Phalanx	Proximal Phalanx	Digital Arteries

Reflectance	32%	26%	34%	47%	26%	53%

Transmittance	68%	74%	66%	53%	74%	47%


Diagnosis	Number OFSO patients	First line OFSO	Salvage OFSO

Chronic frontal sinusitis	23	7/23 (30%)	16/23 (70%)

Frontal sinus mucocele	11	8/11 (72%)	3/11 (28%)

Total inflammatory frontal sinus disease patients	34	15/34 (44%)	19/34 (56%)


Systematic name or TIGR identifier	Description

Tc00.1047053506811.120	Hypothetical protein 1 (HYPO1)

UP|Q9NIQ8 (Q9NIQ8)	Mucin-like protein

UP|Q72DX6 (Q72DX6)	Sensor histidine kinase

UP|Q25325 (Q25325)	Heat shock protein 70-related protein

UP|Q7TPK7 (Q7TPK7)	Ac2-048

UP|Q9XY95 (Q9XY95)	Neurotrophin

UP|H2A_TRYCR (P35066)	Histone H2A

UP|RL29_DROME (Q24154)	60S ribosomal protein L29 (L43)

UP|RS6_LEIMA (Q9NE83)	40S ribosomal protein S6

PDB|1II2_A.0|17942708|	1II2_A Chain A, Crystal Structure Of Phosphoenolpyruvate Carboxykinase (Pepck)

UP|O48239 (O48239)	Cytochrome b (Fragment)

gb|L22334.1|TRBS3RRBN	5.8S ribosomal RNA, internal transcribed spacers 1–7, and 28S ribosomal RNA


Attributes	Format

Date	MM/DD/YY

Time	(H) H:MM (military time)

Count	Number of cars measured for the previous five minutes

Beginning event time	HH:MM:SS (military)

Ending event time	HH:MM:SS (military)

Away team	—

Game attendance	—

W/L score	—


Characteristic	Community level (n=32)	Patch level (n=62)

Communities in cattle corridor (percent)	59.7%	–

Perceived patch condition (percent)

 Bad		9.80%

 Average		42.70%

 Good		47.50%

Patch usage by community members (percent)	40%	30%

Area of communal grazing land (hectares)*	24	6

Grazing lands with use restrictions (percent)*		8.06%


Practice Visitor as:	Assessor	Expert/Educator	Facilitator	Interpreter

Whose role is:	External assessment against standards.	Knowledge and skill transfer.	Consensus building to achieve group view.	Helping practice teams decide what and how they would like to improve.

Based upon:	Historical competence.	Best practice.	A template for process.	Practice based issues.

Controlling:	Outcome.	Outcome and process.	Process.	Neither outcome nor process, simply participation.

Theoretical basis:	Systems.	Systems and organisational development.	Organisational development.	Complexity.

Examples:	Accreditation systems.	Outreach project to set up systems for chronic disease management.	Maturity Matrix.	Action research.


	Fatigue factor:Eigenvalue=3.357% variance=30.52	DB factor:Eigenvalue=1.50% variance=13.62	RT:Eigenvalue=1.33% variance=12.14

Drive late at night	0.774

Drive after prolonged work	0.774

Drive for long periods	0.734

Drive when tired	0.638

Drive with a cold	0.470

Lapses of concentration		0.794

Speeding		0.747

Miss warning signs		0.687

Hostility to others		0.434

Risks at work			0.865

Risks outside work			0.860


Variable	Control factor	Coded value	Uncoded value

x1	Coating weigh gain	−0.6566	9.0302

x2	Duration of coating	0.5152	29.8176

x3	Amount of plasticizer	1	120


Pretreatments	Weighted average degree of polymerization

Untreated Solka-Floc cellulose (control)	1, 110

Dilute acid	260

Dilute acid/Fe2+	150


	Depressive disorders	Anxiety disorders

Hypertension (-)	Hypertension (+)	P-value	Hypertension (-)	Hypertension (+)	P-value

Total	89	6		67	11

Maternal age

< 35 years	32	4	0.29	49	6	0.14

≥ 35 years	57	2	Reference	18	5	Reference

Parity

Nulliparity	53	4	Reference	41	7	Reference

Multiparity	40	2	0.97	26	4	0.85

Medication

No	23	2	Reference	30	4	Reference

Yes	64	4	0.91	32	2	0.67

Self-interruption	2	0	0.32 and 0.23*	5	5	0.03 and < 0.01*

Economic problems

No	85	6	Reference	56	10	Reference

Yes	4	0	0.6	11	1	0.87


		Number of Cancer Patients Treated2

Study Site	Total PopulationService Area1	Breast	Colorectal	Prostate	Lung	Other	TOTAL

Billings Clinic, Montana	283,828	186	133	207	150	753	1,429

Christiana Hospital, Delaware	571,322	533	258	367	447	1258	2,863

Hartford Hospital, Connecticut	1,054,456	544	217	479	280	1075	2,595

Our Lady of the Lake Regional Medical Center, Louisiana	672,319	362	250	365	539	1075	2,591

St. Joseph's/Candler, Georgia	385,242	227	124	87	253	366	1,057

St. Joseph's, Orange, California	2,432,932	385	147	118	149	728	1,527

Sanford USD Medical Center, South Dakota	489,576	187	147	139	177	586	1,236

Spartanburg Regional Hospital, South Carolina	353,757	244	136	193	253	553	1,379

Ascension Health, based in Missouri: St. Vincent Indianapolis Hospital, Indianapolis, Indiana	1,951,252	573	219	182	287	1934	3,195

Columbia St. Mary's Hospital, Milwaukee Wisconsin	685,066	417	157	227	169	692	1,662

Seton Family of Hospitals, Austin, Texas	1,544,670	371	171	58	300	1132	2,032

Catholic Health Initiatives, based in Colorado: Penrose-St. Francis Health Services, Colorado Springs, Colorado	477,263	208	156	197	110	552	1,223

St. Joseph Medical Center, Towson, Maryland	633,814	205	128	155	124	463	1,078

CHI Nebraska coordinated regional program: Good Samaritan Hospital, Kearney, Nebraska	205,994	87	67	95	77	227	553

St. Elizabeth Regional Medical Center, Lincoln, Nebraska	256,939	215	114	39	87	317	772

St. Francis Medical Center, Grand Island, Nebraska	106,724	104	106	82	59	208	559

TOTAL	12,105,154	4848	2530	2990	3461	11919	25,751


Species	Year	Captures	Odds ratio of capture on pipeline

On pipeline	Off pipeline

D. ordii	1997	35	106	1.663

1998	57	116	2.473

1999–2001	21	21	5.037

P. flavescens	1997	0	27	0

1998	5	44	0.572

1999–2001	13	75	0.873


Treatment	N	Mean survival ± SE	95% CI

Nonsurgical	533	67 ± 3 months	62–72

Surgical	751	87 ± 4 months	80–95

Overall	1284	83 ± 3 months	78–88


DDS	SDDS

Food group	Note	Food group	Note

All starch staples	With a threshold of 10 g	Refined grains and cereals	With a threshold of 10 g

	Other cereals and grains	With a threshold of 10 g

	Starch tubers and roots	With a threshold of 10 g

Vitamin A-rich vegetables & fruit	With a threshold of 10 g	Vitamin A-rich dark-green leafy vegetables	With a threshold of 10 g

	Vitamin A-rich deep yellow/orange/red vegetables	With a threshold of 10 g

	Vitamin A-rich fruits	With a threshold of 10 g

All other fruits	With a threshold of 10 g	Vitamin C-rich vegetables	With a threshold of 10 g

All other vegetables	With a threshold of 10 g	Vitamin C-rich fruits	With a threshold of 10 g

		All other fruits & vegetables	With a threshold of 10 g

All legumes & nuts	With a threshold of 10 g	All legumes & nuts	With a threshold of 10 g

Oil and fat	With a threshold of 2 g	Oil and fat	With a threshold of 2 g

Meat, poultry, fish	With a threshold of 10 g	Meat, poultry, fish	With a threshold of 10 g

	Organ meat	With a threshold of 10 g

All dairy	With a threshold of 10 g	All dairy	With a threshold of 10 g

Eggs	With a threshold of 10 g	Eggs	With a threshold of 10 g

Other food	Exclude calculation	Desserts, candy, sugar-sweetened beverages and Puffing Food	With a threshold of 10 g

	Other food	With a threshold of 10 g


 	Estimated effect on baseline physical activity (minutes per day)	Estimated effect on physical activity trajectories (minutes per day per semester)

 	Fixed effect	P value	Fixed Effect	P value

Student Characteristics

Gender

 Female	−12.5 (2.04)	<0.0001	0.596 (0.598)	0.3194

 Male	Referent	 	Referent

Baseline physical activity

 Low	−47.7 (1.50)	<0.0001	7.11 (0.707)	<0.0001

 Moderate	−25.8 (1.51) 	<0.0001	4.20 (0.719)	<0.0001

 High	Referent	 	Referent

BMI status

 Overweight or obese	1.92 (3.21)	0.5512	−0.785 (0.901)	0.3894

 Healthy weight	Referent	 	Referent

 Missing	1.88 (2.35)	0.4252	−0.0527 (0.657)	0.9362

School neighbourhood characteristics

School location

 Rural	−10.6 (2.25)	<0.0001	1.49 (0.658)	0.0234

 Urban	Referent	 	Referent

Socioeconomic status

 Low	−9.09 (2.27)	<0.0001	1.75 (0.664)	0.0086

 High	Referent	 	Referent


	Link with violence

Antisocial

Social norms	No specific reference within literature.

Deceitfulness	No specific reference within literature.

Impulsivity	Related to more violent assaults [41].Did not directly predict aggression once emotional dysregulation was controlled for [40].Impulsivity related to history of persistent violence [27]

Aggressiveness	Disturbed batterers more physically aggressive [7].Aggressiveness related to ASPD and NPD diagnoses. In BPD aggressiveness linked to poor impulse control. [19].

Reckless	Related to more violent assaults [41].

Irresponsibility	No specific reference within literature.

Lack remorse	No specific reference within literature.

Borderline

Avoid abandonment	Avoidant attachment predicted severity of physical partner violence mediated by interpersonal difficulties [31].Female offenders have greater number of traumatic experiences and less secure attachment styles [22].ASPD and BPD diagnoses mediated path between by avoidant attachment intimate partner violence [34].

Unstable relationships	See ‘Avoid Abandonment’.

Identity disturbance	No specific reference within literature.

Impulsivity	See ‘Impulsivity’ under Antisocial diagnosis.

Suicidal behavior	No specific reference within literature.

Affective instability	Emotional Dysregulation predicted physical assault [40].

Emptiness	No specific reference within literature.

Anger	Impulsivity predicted physical aggression and trait anger. Trait anger mediates relationship between impulsivity and physical aggression. [42].

Paranoid ideation	Disturbed batterers higher levels of paranoid ideation [7].

Narcissistic

Grandiose	Link between experience grandiose delusions and serious violence. Stronger link to violence when associated with elation or anger [49].

Fantasies of success	No specific reference within literature.

Is “special”	See ‘Grandiose’.

Excessive admiration	No specific reference within literature.

Sense of entitlement	Evidence of inflated sense of entitlement linked to violent offenders. When violated more likely to be violent [18]

Exploitative	No specific reference within literature.

Lacks empathy	Violent offenders have reduced ability to recognise facial emotions [41].Poor perspective taking exacerbated anger arousal [9].Violent offender have poorer empathy [7].

Envious	No specific reference within literature.

Arrogant	No specific reference within literature.


Characteristic	Ranking from electronic survey	Ranking from paper survey

Impact on care	1	2

Strength of supporting evidence	2	1

Local health needs of patients/clients	3	3

Costs associated with new ways of working	4	4

Local expertise	5	5

Meeting minimum standards	6	6

National or local priority	7	7


Property	Explanation

Citation-related properties

occursInChecklist	Reference to a species checklist

auctorumYear	The year of original publication

completeAuctorumString	Author name(s) expressed according

	to the established practices of taxonomy

Name-related properties

hasNonvalidName	Expresses synonyms, homonyms

	and orthographic variants of a valid

	scientific name

hasVernacularName	The common name equivalents for

	the scientific names

hasNomenclaturalCode	Specifies the set of rules that are applied

	(ICN [55] or ICZN [56])

hasVernacularNameStatus	Expresses whether a common name is

	accepted or an alternative one

rdf:type	Expresses the hierarchical level in

	a classification. The ranks are obtained

	from TDWG Taxon Rank LSID Ontology [57].

	Every taxon is an instance of a specific

	taxonomic rank and the class

	TaxonInChecklist (Figure 3).


Item*	Affirmative responses (%)**	Item calibration***	SE****	Item infit	Item outfit

AD1 Worried food would run out	48.7	3.45	0.078	0.76	1.85

AD2 Food ran out; did not have money for more	53.1	2.86	0.085	0.95	1.47

AD3 Could not afford to eat nutritious meal	50.9	3.17	0.081	0.97	4.20

AD4 Cut size of meal or skipped meal	26.7	5.90	0.077	1.03	1.80

AD5 Ate less than thought he/she should	21.3	6.58	0.084	0.90	1.62

AD6 Hungry but did not eat	13.2	7.93	0.101	0.76	0.81

AD7 Lost weight	10.3	8.60	0.113	1.09	2.03

AD8 Did not eat for whole day	7.2	9.51	0.134	1.05	1.14

Mean		6.00

Standard deviation		2.44

Discrimination parameter		1.00

Number of cases*****	2,003	1,241	1,241	1,241	1,241


Groups	Normoglycemic(n = 10)	Hyperglycemic(n = 10)	Hyperglycemic + vitamin C (n = 9)

Sperm number in the cauda epididymis (×106)	111.00 [90.00 - 131.00] a	40.16 [33.05 - 71.00] b	43.00 [42.63 - 73.80] ab

Sperm transit time in the cauda (days)	3.43 [3.30 - 4.65] a	1.56 [1.25 - 2.70] b	2.14 [1.72 - 2.88] ab


Plant	Feedstock	Volume of AD digesters (m3)	Dry matter content in digesters (%)	Organic loading in digesters (kg/day⋅m3)	Methane content in biogas (%)	Installed CHP power (kW)	Electricity generation (MWh/year)	Electricity consumption (MWh/year)	Heat generation (MWh/year)	Heat consumption by AD (MWh/year)

Plant 1	• Pig slurry• Tomato peel and seeds• Maize silage	1650	8.7	0.92	52.8	230	1945	173	2549	809

Plant 2	• Pig slurry• Maize silage	2250	10.6	1.07	52.6	300	2429	206	3184	814

Plant 3	• Pig slurry• Maize silage• Maize ear silage	2000	9.7	0.98	52.7	300	2505	276	3514	799

Plant 4	• Maize silage	2 × 2750	10.7	3.40	52.1	999	7972	717	8771	2505

Plant 5	• Cow slurry	1850	8.5	0.58	56.0	100	781	86	1095	547


Medicine	MIC (mg/L)

AMPH-B	0.25

5-FC	<=0.12

MCZ	0.06

FLCZ	8

ITCZ	0.12

MCFG	<=0.015

VRCZ	0.25


Diagnosis	Intervention	Number of Patients	Reference

Evidence from Pediatric Studies

msk pain/soft tissue injury	analgesic	17	Clark 2003[10]

Asthma exacerbation	inhaled β-agonist	12	Travers 2001[11]

radial fracture	reduction & cast	10	McLauchlan 2002[12]

otitis media	PO antibiotics	10	Kozyrskyj 2000[13]

dehydration (failed PO rehydration)	IV rehydration	6	Atherly-John 2002[14]

bronchiolitis	salbutamol	6	Kellner 2000[15]

dehydration	PO rehydration	5	Atherly-John 2002[14]

urinary tract infection	PO antibiotics	5	Hoberman 1999[16]

constipation	suppository/enema	5	Dashshan 1999[17]

laceration	sutures	4	Barnett 1998[18]

croup	PO steroids	4	Ausejo 2000[19]

suspected occult bacteremia	IM/IV antibiotics	3	Bass 1993[20]

tonsillitis	PO antibiotics	3	Del Mar 2000[21]

urticaria	cetirizine	2	Simons 2000[22]

Kawasaki Syndrome	IVIG & ASA	2	Newburger 1986[23]

alcohol intoxication	intubation	2	Gausche-Hill 2000[24]

generalized tonic-clonic seizure in known epileptic	increase clobazam dose	1	Booth 1998[25]

radial head subluxation	reduction by hyperpronation	1	Macias 1998[26]

epistaxis	silver nitrate	1	Ruddy 1991[27]

behavior problems	referral for counselling	1	Dishion 1995[28]

bronchiolitis	racemic epinephrine	1	Menon 1995[29]

viral conjunctivitis	polysporin ointment	1	Isenberg 2002[30]

laceration	tissue glue	1	Barnett 1998[18]

constipation	polyethylene glycol	1	Dashshan 1999[17]

dog bite	IV antibiotics & debridement	1	Medeiros 2001[31]

burn	delayed graft	1	Desai 1991[32]

reflux esophagitis	conservative reflux measures	1	Craig 2004[33]

pain (following MVC trauma)	morphine infusion	1	Hendrickson 1990[34]

reflux esophagitis	ranitidine	1	Cucchiara 1993[35]

varicella zoster	supportive care	1	Klassen 2002[36]

atopic dermatitis	hydrocortisone cream	1	Alonso 1999[37]

meningitis exposure (H flu)	PO antibiotics	1	Daum 1981[38]

dislocated patella	relocation under sedation	1	Nikku 1997[39]

Evidence from Adult Studies

migraine headache	metoclopramide	3	Colman 2003[40]

proximal humerus fracture	cast & sling	3	Gibson 2003[41]

ankle fracture	cast	2	Phillips 1985[42]

gastritis	antacids	1	Moayyedi 2003[43]

clavicle fracture	sling	1	Andersen 1987[44]

prozac overdose (2 hours previous)	supportive care	1	Yeates 2000[45]

tibial fracture	internal fixation	1	Wyrsch 1996[46]

epididymitis	PO antibiotics	1	Redfern 1984[47]

panic attack	sublingual short-acting benzodiazepine	1	Dunner 1986[48]

aphthous ulcers	viscous lidocaine	1	Saxen 1997[49]

fracture T12 vertebrae	T11–12 instrumentation & fusion	1	Shen 2001[50]

aggression	haloperidol & lorazepam	1	Gillies 2001[51]

tibial fracture	reduction & cast	1	Abdel-Salem 1991[52]

acetaminophen overdose	N-acetylcysteine	1	Brok 2002[53]

gastrostomy tube fell out	insertion of foley catheter	1	Kadakia 1994[54]

increased intracranial pressure	mannitol	1	Schierhout 2003[55]

migraine headache	NSAID	1	Bussone 1999[56]


Category/name	Function	Change (x-fold)

Cellular defense

 HSP27	Protein stabilisation	++

Apoptosis/degeneration

 Cathepsin Z	Lysosomal proteolysis	++

Proliferation

 Annexin	Growth factor	++

Migration

 Cofilin	Actin turnover	+++

 Tropomodulin 3	Actin turnover	++++++

 CLIM1	Actin kinase adaptor	++++++

 Galectin	Cell to cell interaction	++

 β-Hexosaminidase β-subunit	Glycosidasis	++++++

Metabolism

 Pyruvate kinase 3	Glycolysis	−

 Enolase 1	Glycolysis	−

Nuclear transport

 Ran-binding protein 1	RanGAP activity	++

 elF5A	Cofactor in nuclear export	++++++

Translation

 CRHSP-24	Translation regulating protein	++++++


Patient	Location of sample	Size of sample(Average;mm2)	Number of samples taken

P01	Central and peripheral	30	3

P02	Central	24	4

P03	Central	40	3

P04	Central and peripheral	20	4

P05	Central	24	3

P06	Central	80	3

P07	Central and peripheral	66	2

P08	Central and peripheral	72	3


		Enrichment score+	Protein count (%)	Protein ID	P value

Biological process	Regulation of response to external stimulus	2.3	3 (27.27)	AHSG, C3, HRG	4.69e-3

	Cellular iron ion homeostasis	2.13	3 (27.27)	HAP, HPX, TF	1.81e-4

	Iron ion homeostasis	2.13	3 (27.27)	HAP, HPX, TF	2.45e-4

	Cellular di-, tri-valent inorganic cation homeostasis	2.13	3 (27.27)	HAP, HPX, TF	9.34e.3

	Di-, tri-valent inorganic cation homeostasis	2.13	3 (27.27)	HAP, HPX, TF	1.03e-2

	Cellular cation homeostasis	2.13	3 (27.27)	HAP, HPX,TF	1.16e-2

Molecular function	Endopeptidase inhibitor activity	2.3	3 (27.27)	AHSG,C3, HRG	3.32e-3

	Peptidase inhibitor activity	2.3	3 (27.27)	AHSG, C3, HRG	3.69e-3

	Enzyme inhibitor activity	2.3	3 (27.27)	AHSG, C3, HRG	1.11e-2

Cellular component	Extracellular region	8.11	11 (100)	A1BG, AHSG, APOA1, AZGP1, C3, FGG, HAP, HPX, HRG, LRG1, TF	2.66e-11

	Secretory granule	2.31	4 (36.36)	APOA1, FGG, HRG, TF	3.06e-4

	Cytoplasmic membrane-bounded vesicle	2.31	4 (36.36)	APOA1, FGG, HRG, TF	7.58e-3

	Membrane-bounded vesicle	2.31	4 (36.36)	APOA1, FGG, HRG, TF	8.29e-3

	Cytoplasmic vesicle	2.31	4 (36.36)	APOA1, FGG, HRG, TF	1.16e-2


 	 	Assessment

Outcomes	Measures	t1	t2	t3	t4

Self-management competence (primary outcome)	Health education impact questionnaire heiQ, German version [29]. Subscales Self-monitoring and insight, Skill and technique acquisition	X	X	X	X

Kansas City Cardiomyopathy Questionnaire KCCQ, German version [30]. Subscale self-efficacy	X	X	X	X

Determinants of behavior:

Intention, action and coping planning, action control	HAPA-scales [31,32]	X	X	X	X

Medication beliefs	Beliefs about Medicine Questionnaire BMQ-D [33], German version	X	X	X	X

Self-management behavior:

Symptom control	Questionnaire will be developed by our research group	X	---	X	X

Physical activity	Godin Leisure-Time Exercise Questionnaire [34], German modified version	X	---	X	X

Medication adherence	Medication Adherence Report Scale MARS-D, German version [35]	X	---	X	X

Health-related quality of life (disease specific)	Kansas City Cardiomyopathy Questionnaire KCCQ, German version [30]	X	X	X	X

Treatment satisfaction	Short questionnaire developed by our research group [36]	---	X	---	---


	Hypermethylated	Hypomethylated

n	3925	4615

CpG island location	CpG islands	Non-CGI

Genomic location	TSS, 1st exon	Gene body, outside genes

Associated genes	1832	2057

GO function terms	36	27

GO process terms	265	53

Canonical pathways (IPA)	19	3

Transcription factors	24	1


	DNA binding consensus sequence	Putative binding site found in putative ATRX promoter	Biological roles	References

5'UTR of ATRX (+215 to +1)

YY1(+38 to +29)	SNCCATNTT	CGCCATTTT	Activator/repressor involved in neural development with roles in the testis and meiosis	[35,36]

ATRX promoter region

Inr element(-2 to +3)	CTTNACC	CTTAACC	Binds to basal transcription factor TFIID	[19]

CCAAT boxes(-2 to +3)(-38 to -34)(-69 to -65)	CCAAT	CCAAT	Binds NF-Y, C/EBP, GATA1, NF-E3	[42]

E2F(-6 to -1)	TTTGGCGC	ATTGGCGC	Family of TFs that regulate mitosis, apoptosis, DNA repair, development and differentiation	[52]

CREB(-122 to -117)	TGACGTCA	CGACGTCA	Mediation of basal and PKA-inducible transcription	[65]

HNF4(-173 to -168)	TGACCT	TGACCT	Liver factor involved in liver development and digestive function	[66]

CR1

STAT5B(-963 to -956)	TTCN3GAA	TTCAAGAA	Involved in immune response, erythropoesis and mammary development	[67]

CP2(-1017 to -1003)	A/TCTGG-CNRGN6CNRS	CTATT-CCAGN6GCAG	Regulates transcription of SRY. Initially shown to bind murine alpha-globin gene	[50]

E2F (-796 to -791)	TTTGGCGC	TTTGGCTG	See E2F above	[52]

CR2

HNF6(-1413 to -1408)	GAATCA	GAAGCY	Liver factor involved in regulation of HNF4 and pancreatic precursor cells	[68]

CR3

FOXJ2/NKX2-5(-12720 to -12714)	TNAAGTG	TTAAGTA	Involved in regulation of cardiogenesis	[69]


Titer of serum from one sheep infected intrapulmonarily with 300.000 TCID 50 of virus K796	Virus strains

K796	10B	7W

Serum 13 months after infection with K796	128	16	8

Serum 3 years after infection with K796	256	32	16

Titer of serum from one naturally infected sheep in Cyprus	16	128	128


Traits/Disease	No. of Putative Associations

Conduct disorder (case status) *	11

Ischemic stroke	11

Atrial fibrillation/atrial flutter*	10

Permanent tooth development*	10

Conduct disorder (symptom count)*	9

Primary tooth development (time to first tooth eruption)*	8

Cleft lip*	7

Primary tooth development (number of teeth)*	5

Alcoholism (alcohol dependence factor score)*	4

Plasma coagulation factors*	3

Vitamin D insufficiency*	3

Vitamin D levels*	2

Atrial fibrillation*	1

Nonsyndromic cleft lip with or without cleft palate*	1

Plasma levels of Protein C*	1

Total	86


HbB Genotype	Numbers (87)a	G6PD Genotype	Numbers (84)a	68 Status	126 Status	Deduced Phenotypeb

		68–126

AA	75 (86%)	VV-NNc	51 (61%)	Wildtype	Wildtype	G6PD B

SS	0	VV-DDd	8 (10%)	Wildtype	Mutant	G6PD A

AS	12 (14%)	M-De	6 (7%)	Mutant	Mutant	G6PD A-

AC	0	VM-ND	10 (12%)	Single Mutant	Single Mutant	G6PD A

CC	0	VV-ND	8 (9%)	Wildtype	Single Mutant	G6PD A

SC	0	VM-DD	1 (1%)	Single Mutant	Mutant	G6PD A

No PCR-product	3	No PCR-product	6


	Rape NOS	Gang Rape	Sexual Slavery	Combined Gang Rape and Sexual Slavery

	Number	Percent	Number	Percent	Number	Percent	Number	Percent

Physical:

 Pelvic pain	53	24.2	139	23.0	3	6.0	25	21.0

 Lumbar pain	24	11.0	72	11.9	0	0	16	13.4

 Abdominal pain	22	10.0	41	6.8	1	2.0	6	5.0

 Pregnancy	12	5.5	13	2.1	20	40.0	17	14.3

 Malaise	10	4.6	44	7.3	1	2.0	6	5.0

 Vaginal discharge	10	4.6	36	6.0	1	2.0	8	6.7

 Vaginal itching	9	4.1	25	4.1	1	2.0	8	6.7

 Abnormal menses	10	4.6	26	4.3	1	2.0	6	5.0

 Generally unwell	5	2.3	24	4.0	0	0	5	4.2

Social:

 Loss of possessions	55	25.1	147	24.3	10	20.0	19	16.0

 Loss of child/spouse	13	5.9	75	12.4	2	4.0	21	17.6

 Spousal abandonment	6	2.7	43	7.1	3	6.0	10	8.4

 Loss of other family	2	0.91	15	2.5	0	0	9	7.6

 Loss of home	1	0.46	9	1.5	0	0	1	0.84

Psychological:

 Anxiety about rape	53	24.2	154	25.5	18	36	31	26.1

 Anxiety about spousal abandonment	6	2.7	38	6.3	4	8	9	7.6

 Concern about STIs	25	11.4	76	12.6	4	8	19	16.0

 Concern about HIV	14	6.4	56	9.3	4	8	13	10.9

 General health concerns	16	7.3	66	10.9	7	14	9	7.6

 Grief about loss of spouse	9	4.1	40	6.6	1	2	10	8.4

 Grief about loss of child/children	8	3.7	25	4.1	0	0	3	2.5


	Key inclusion and exclusion criteria	Orchard et al. [7]	Meisser et al. [8]	Noehren et al. [11]	Ferber et al. [12]	Phinyonmark et al. [20]	Foch et al. [21]	Foch and Milner [22]	Foch and Milner [23]	Grau et al. [24]	Hein et al. [25]	Miller et al. [26]a	Miller et al. [27]a	Noehren et al. [28]

1	Clear definition of location of pain was reported	✓	✓	X	✓	✓	✓	X	X	✓	✓	X	X	✓

2	Reports a typical history of ITBS with symptoms consistent to the condition	✓	X	X	✓	✓	✓	X	X	✓	✓	X	✓	✓

4	Diagnosis was confirmed by a medical practitioner/physiotherapist/ trainer	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓

4	A positive clinical test (Obers/Nobles)/ palpation	✓	✓	X	X	✓	X	X	X	✓	✓	X	✓	✓

5	No previous knee surgery	✓	X	✓	✓	✓	X	✓	✓	✓	✓	✓	X	✓

6	No internal derangement or other sources of lateral knee pain present	✓	✓	✓	✓	✓	X	✓	✓	✓	✓	✓	X	✓

7	No previous spine or lower limb injury	✓	✓	✓	✓	✓	X	X	✓	✓	✓	✓	X	✓

Criteria’s Met	7	5	4	6	7	3	3	4	7	7	4	3	7


	Ordinary light	Infrared ray light

ICG-positive nodedetection	28/36(78 %)	36/36

The number ofICG-positive nodes	3.4 ± 3.7*(0 to 16)+	9.2 ± 5.9*(2 to 25)+

Lymph nodemetastasis sensitivity	1/5(20 %)	5/5(100 %)


Test 	Day 0 (admission)	Day 13 (discharge)

Coxsackie A9 (NT)	8 Units	16 Units

Coxsackie B1 (NT)	16 Units	32 Units

Coxsackie B2 (NT)	<4 Units	<4 Units

Coxsackie B3 (NT)	32 Units	64 Units

Coxsackie B4 (NT)	<4 Units	<4 Units

Coxsackie B5 (NT)	<4 Units	<4 Units

Coxsackie B6 (NT)	<4 Units	<4 Units


Who Would Use the App?	When Would They Use the App?	How Useful Is an App?	What Should Be in the App?	Who or How Should It Be Advertised to Users?

Parents of children ages 0–6First time momsParents about to switch their child to a new seatCaregiversFamilyBabysittersDads say they are less likely to use it but moms say dads would use it a lot	Before the baby is bornWhen buying a new seat (process) or about to switch seatsExternal caregiver installingFirst time installation with new seatWhen looking for car seat check pointsTroubleshootingIn need of non-installation factoids/frequently asked questions (expiration dates) 	AdvantagesOn the go informationSimple to useAccessibleProvides direct infoEasier to readVisual assistanceDisadvantagesSome preferred websiteApps may be difficult to navigateUnfamiliarity with appsNot useful when installing—“keep checking your phone”	Car seat check locator and appointment schedulerWhat seat fit best in the carHow to install in different types of carsConsumer product reviewsCar seat laws and policiesTypes of car seats for height, weight, and ageFAQ’s, safety myths vs. factsExpiration datesTravelingOnline forum (social tools)Search functionMultiple languagesSpanishVideos and imagesTroubleshooting info and tools—inch and pinch test	Who:Not manufacturersDoctors in officeCHOPInsurance companiesSafekids WorldwideHow:No brochuresParent magazinesWebsite of CRS companiesPoster in waiting roomPrenatal and parenting classes


Organizational	Socio-cultural	Intrinsic

Motivators

• Opportunities for higher qualifications	• Respect	• Serving people

• Good working and hygienic conditions	• Social rewards	• Work interest

• Personal safety		• Career growth

• Good professional experience		• Ability to support oneself and family

• Good pay		• Autonomy

• Financial incentives other than pay		• Empowerment

Demotivators

• Less pay	• Disrespect	• Less career growth

• Poor working and hygienic conditions	• Poor interpersonal relations	• Inability to support oneself and family

• Fewer opportunities for higher qualifications	• Less social rewards

• Less personal safety	• Less personal and social time

• Heavy work load

• Long duty hours

• Resource unavailability

• Fewer promotion opportunities

• Poor supervision


Cost variable	Source	Unit cost in public system (Dollar)	Unit cost in private system (Dollar)

Medical visit

Public	Hospital accounts department/DMA	5*	125 (range 100-150)

Medication

Pain killer	Central Medical Store	0.05/500 mgx2×3=0.30**	2.00

ORS	Central Medical Store	0.75/packx3=2.25	4.5×3=13.5

Antibiotics	Central Medical Store	0.03/250 mgx3×3×5=1.35***	8.00

Gravol	Central Medical Store	0.05/50 mgx4×2=0.4****	2.00

Loperamide	Private dispensary	0.50/2 mgx2=1.0*****	2.00

IV fluid (0.9% sodium solution)	Central Medical Store	3.42/litre

Testing of stool specimens	Billing department, PMH	20.00

Loss of working days

Caregiver service	Labour standard order (Minimum wage)	28.75/day

Duration of illness	Population survey	2 days (Median value)


Neuroprotectant	n (%*)

Edaravone	95 (8.4)

Ganglioside GM1	29 (2.6)

Cattle encephalon glycoside and ignotin	112 (9.9)

Cinepazide	56 (5.0)

Citicholine	334 (29.6)

Other†	198 (17.5)

Unspecified	321 (28.4)


Self-rated spiritual health	Ideators (%)	Non-ideators (%)	χ2	p-Value

Excellent OR good	117 (49.37)	2713 (85.10)	196.23	<.0001

Fair OR poor OR uncertain	120 (50.63)	475 (14.90)


Variable	Controls (n = 73)	Participants (n = 73)	p valuea

Lipoprotein subclassb

VLDL and chylomicron particle concentrations (nmol/L)

 Total VLDL and chylomicron particles	82.0 ± 45.3	87.5 ± 39.6	0.15

 Large VLDL and chylomicron particles	4.6 ± 6.3	8.2 ± 6.8	< 0.01c

 Medium VLDL particles	38.1 ± 28.5	39.7 ± 25.7	0.50c

 Small VLDL particles	39.3 ± 19.9	39.7 ± 17.2	0.90

LDL particle concentrations (nmol/L)

 Total LDL particles	1253 ± 367	1437 ± 477	0.01

 Large LDL particles	337 ± 211	251 ± 218	< 0.01c

 Intermediate LDL particles	45.8 ± 38.5	72.6 ± 50.2	< 0.01c

 Small LDL particles	870 ± 434	1113 ± 478	< 0.01

HDL particle concentrations (μmol/L)

 Total HDL particles	34.7 ± 6.7	32.1 ± 5.6	0.01

 Large HDL particles	6.4 ± 3.5	4.6 ± 3.4	< 0.01

 Medium HDL particles	5.2 ± 4.9	5.9 ± 4.8	0.25c

 Small HDL particles	23.1 ± 7.0	21.7 ± 5.8	0.17

Mean particle sizes (nm)

 VLDL size	50.6 ± 9.0	55.6 ± 10.4	< 0.01

 LDL size	20.7 ± 0.9	20.2 ± 0.8	< 0.01

 HDL size	8.9 ± 0.4	8.6 ± 0.3	< 0.01

Physiological variablesd

 Age	60.0 ± 7.8	60.3 ± 8.0	0.79

 Body mass index (kg/m2)	28.2 ± 3.7	34.0 ± 7.0	< 0.01

 Systolic blood pressure (mm Hg)	133 ± 17	136 ± 17	0.12c

 Diastolic blood pressure (mm Hg)	78.9 ± 9.2	80.8 ± 9.8	0.50c

 HDL-cholesterol (mg/dl)	50.5 ± 13.7	43.7 ± 13.1	< 0.01c

 LDL-cholesterol (mg/dl)	111 ± 33	111 ± 39	0.64c

 Total cholesterol (mg/dl)	191 ± 42	193 ± 47	0.82

 Triglycerides (mg/dl)	148 ± 100	189 ± 99	< 0.01

 Physical fitness (Bruce score)	10.4 ± 2.8	6.6 ± 2.2	< 0.01

 Framingham risk (× 100)	7.4 ± 6.8	10.7 ± 8.5	0.02c


	Regular expression method		Term voting method

TOTAL terms	98435	100%	98435	100%

Selected set	13755	14%	13755	14%

Excluded set	84680	86%	84680	86%

Sample of excluded	3140	100%

Wrong (false negative)	49	1.6%

Correct (true negative)	3091	98.4%

Proportionate number of bona fide terms in excluded set	1321

Sample of included	2070	100%	2287	100%

Wrong (false positive)	1538	74.3%	1974	86.3%

Correct (true positive)	532	25.7%	313	13.7%

Probable number of bona fide terms in selected set	3535		1883

Recall	0.728

Precision	0.257		0.137


Target gene	Forward primer (5′ to 3′)	Reverse primer (5′ to 3′)	Source

Mad2	GAGTTCTTCTCATTCGGCATCA	CCAATCTTTCAGTTGTTCCACC	PrimerBank

Bub1	TGCTGCACAACTTGCGTCTAC	TCAACGCCCAACTCTGCCT	PrimerBank

APC	CCAACAAGGCTACGCTATGC	ATCTGCTCGCCAAGACAAAT	PrimerBank

β-actin	ATCATGTTTGAGACCTTCAACA	CATCTCTTGCTCGAAGTCCA	PrimerBank


Inner cortical width of thoracic pedicles (mm)	No. of thoracic pedicles instrumented	No. of thoracic pedicles accurately instrumented	Accuracy (%)

0–1.0	194	68	35.05

1.1–2.0	176	115	65.34

2.1–3.0	352	304	86.36

≥3.1	376	339	90.16

Total	1098	826	75.23


EDA-Q items (18 items)	Corresponding DISCO items (17 items)	DISCO variables

Obsessively resists and avoids ordinary demands	Lack of co-operation	LACKCOP

Has difficulty complying unless carefully presented

Is driven by the need to be in charge	Using age peers as mechanical aids, bossy and domineering	CPEERAD*

Tells other children how to behave

Finds everyday pressures intolerably stressful	Anxiety	ANXIETY

Mimics adult mannerisms and styles	Repetitive acting out roles	CTROL*

Shows little shame or embarrassment	Behaviour in public places	BEHAPUB

Embarrassing remarks in public	REMARK

Good at getting around others	Apparently manipulative behaviour	MANBEH*

Unaware of differences between self and authority figures	Awareness of own identity	CIDENT*

Attempts to negotiate better terms with adults

If pressurised to do things, may have a ‘meltdown’	Temper tantrums	TEMPER

Mood changes rapidly	Changeable mood	MOODCH

Knows what to do or say to upset specific people	Difficulties with other people	DIFPEOP

Blames or targets a particular person	Harassment of others	HARAS*

Blaming other people	BLAME*

Denies behaviour, even when caught red-handed	Fantasising, lying, cheating, stealing	LYING*

Outrageous behaviour to get out of doing something	Socially shocking behaviour	SHOCK*

Extreme emotional responses to small events	Inappropriate sociability (rapid, inexplicable changes from loving to aggression)	CINAPP*

Social interaction has to be on his/her own terms	One-sided social approaches	CONESID


 	SA-test (reaction time (msec)

Active diet	Control diet

time 0	1320 ± 20	1320 ± 21

45 min	1219 ± 19	1230 ± 21

120 min	1182 ± 21	1202 ± 23


	Treatment-naïve cancer patients (n= 555)

Age, years (IQR)	62 (52-71)

Male gender, n (%)	227 (41%)

BMI kg/m2, (IQR)	25.0 (22.6–28.4)

Comorbidities

 Known CAD, n (%)	28 (5%)

 Heart Failure, n (%)	38 (7%)

 Diabetes mellitus, n (%)	43 (8%)

 Arterial Hypertension, n (%)	250 (45%)

 CKD, n (%)	31 (6%)

 COPD, n (%)	113 (20%)

Cancer disease stage*

 Stage 1, n (%)	96 (17%)

 Stage 2, n (%)	50 (9%)

 Stage 3, n (%)	108 (19%)

 Stage 4, n (%)	183 (33%)

Hepatic involvement

 Primary hepatic, biliary tract or pancreatic malignoma, n (%)	27 (5%)

 Hepatic metastases, n (%)	51 (10%)

Laboratory parameters

 GFR, mL/min/1.73 m2 (IQR)	74.5 (63.7–86.0)

 BUN, mg/dl (IQR)	15 (12-19)

 BChE, kU/l (IQR)	7.31 (6.10–8.40)

 AST (GOT), U/l (IQR)	24 (19–31)

 ALT (GPT), U/l (IQR)	22 (16–32)

 GGT, U/l (IQR)	32 (21–63)

 Bilirubin, mg/dl (IQR)	0.58 (0.44-0.79)

 Albumin, g/l (IQR)	43.0 (40.0–45.4)

 CRP, mg/dl (IQR)	0 (0-1)

 SAA, μg/ml (IQR)	8 (4-26)

 IL-6, pg/ml (IQR)	2 (2–3)


Time points of measurements	IOP	ONSD

T0	Patient awake in supine position before induction of anaesthesia	X	-

T1	20 min after induction of general anaesthesia in supine position	X	X

T2	After insufflation of the abdomen with CO2 in supine position	X	X

T3	After 30 min in 45° Trendelenburg position with the abdomen still insufflated with CO2	X	X

T4	Control of Santorini’s plexus in 45° Trendelenburg position with CO2 still insufflated	X	X

T5	Anaesthetised before awakening in supine position	X	X


Proteins present in all 8 Mimiviridae genomes

CLS10031	A1L transcription factor VLTF-2	CLS10052	Proliferating cell nuclear antigen

CLS10071	A2L transcription factor VLTF-3	CLS10035	protein disulfide Isomerase/thioredoxin family

CLS10199	asnB, asparagine synthetase B	CLS10216	putative DNA-directed RNA polymerase II subunit N

CLS10039	capsid protein	CLS10047	replication factor C small subunit

CLS10262	D5-like helicase-primase	CLS10049	replication factor C small subunit

CLS10015	DEAD/SNF2-like helicase or ATP-dependent RNA helicase	CLS10258	ribonuclease H

CLS10089	DNA directed RNA polymerase subunit L	CLS10041	ribonuclease III

CLS10259	DNA mismatch repair ATPase MutS	CLS10130	ribonucleosidediphosphatereductase large subunit

CLS10104	DNA polymerase elongation subunit family B	CLS10252	ribonucleosidediphosphatereductase small subunit

CLS10201	DNA topoisomerase IB	CLS10028	TATA-box-binding protein

CLS10230	DNA topoisomerase II	CLS10057	Transcription factor S-II (TFIIS)-domain-containing protein

CLS10090	DNA-dependent RNA polymerase subunit Rpb9/M	CLS10055	transcription initiation factor IIB

CLS10250	DNA-directed RNA polymerase subunit 5 (RPB5)	CLS10011	ubiquitin-conjugating enzyme E2

CLS10261	DNA-directed RNA polymerase subunit 6	CLS10214	Ulp1-like protease

CLS10076	DNA-directed RNA polymerase subunit alpha	CLS10066	VV A18-like helicase

CLS10053	DNA-directed RNA polymerase subunit beta	CLS10068	VV A32 virion packaging ATPase

CLS10249	DNA-directed RNA polymerase subunit E’ (RPB7)	CLS10218	YqaJ-like viral recombinase

CLS10024	Erv1 / Alr family oxidoreductase	CLS10212	hypothetical protein

CLS10221	eukaryotic translation initiation factor 4E-like protein	CLS10222	hypothetical protein

CLS10086	FtsJ-like methyltransferase	CLS10233	hypothetical protein

CLS10030	Holliday junction resolvase	CLS10236	hypothetical protein

CLS10056	metallopeptidase WLM	CLS10032	hypothetical protein

CLS10219	mRNA capping enzyme	CLS10043	hypothetical protein

CLS10088	NUDIX hydrolase	CLS10046	hypothetical protein

CLS10224	poxvirus poly(A) polymerase catalytic subunit-like protein	CLS10070	hypothetical protein

CLS10253	probable ubiquitin carboxyl-terminal hydrolase	CLS10081	hypothetical protein

Genes missing in one or two OLPG genomes but present in all the other Mimiviridae genomes

CLS10059	AAA family ATPase	CLS10009	Lon domain protease

CLS10021	chaperone protein DnaJ	CLS10033	patatin-like phospholipase

CLS10022	chaperone protein DnaJ	CLS10072	Prolyl 4-hydroxylase

CLS10082	heat shock 70 kDa protein	CLS10091	thymidylate synthase

CLS10042	hypothetical protein	CLS10010	XRN 5'-3' exonuclease


	MMSE Non-demented	MMSE Demented	EMSE Non-demented	EMSE Demented

Below 5th pcntle (MMSE cut-point = 21, EMSE cut-point = 41)	618 (3%)	622 (73%)	810 (5%)	474 (77%)

Below 10th pcntle (MMSE cut-point = 23, EMSE cut-point = 45)	1443 (8%)	707 (84%)	1676 (10%)	524 (88%)

Below -1 SD (MMSE cut-point = 23.1, EMSE cut-point = 44.5)	2075 (13%)	739 (90%)	1676 (10%)	524 (88%)

Below -2 SD (MMSE cut-point = 12.9, EMSE cut-point-24.5)	5 (0%)	229 (24%)	36 (0%)	125 (19%)


 	Subchondral bone volume	Subchondral bone migration area

 	Pearson's r	P value	Pearson's r	P value

Weeks	0.799	<0.001	0.799	<0.001

Gross appearance	0.865	0.001	0.923	<0.001

Histology	0.649	0.059	0.520	0.152


Country	Study type	Phase	n	Primary objective	Major findings

Thailand	HNV, PK and tolerability	1	24	PK and bio-availability of AS and MQ; administered separately and as a coformulation to healthy volunteers and patients	No difference was seen in the bio-equivalence of MQ in the two formulations; although a difference was seen for AS/DHA, this was not concluded to be clinically relevant[20]

PK, efficacy and safety	2	50	Population PK model of new dosage regime of MQ with AS in loose combination over three days	Splitting the 25 mg/kg dose of MQ into three doses of 8 mg/kg improved oral bio-availability compared to the conventional split-dose regimen results. New regimen was well tolerated and with an equivalent therapeutic response[21]

PK, efficacy and safety	2b	50	Safety and PK of ASMQ FDC vs non-fixed AS+MQ against multi-drug resistant falciparum malaria in adults	FDC well-tolerated with broadly similar PK profiles to non-fixed AS plus MQ[22]. The observed slowing of heart rate was best explained by malaria resolution[23]

Efficacy and safety	3	500	ASMQ FDC with separate tablets in adults and children with uncomplicated multidrug-resistant falciparum malaria	Cure rates were 91.9% for the FDC after 63 days, with a lower incidence of vomiting compared to those in the loose tablets group[24]

Myanmar	Competitive Effectiveness	4	808	Effectiveness of five artemisinin combination regimens with or without PQ in uncomplicated falciparum malaria	ASMQ provided the greatest post-treatment suppression of malaria after 63 days, with the addition of PQ substantially reducing transmission potential of malaria[25]

India	Efficacy and safety	3	77	PCR corrected cure rate of ASMQ FDC in adult patients with uncomplicated falciparum malaria	Mean parasite clearance time of 48 hours

Brazil	Intervention study: PK Efficacy and safety	3b/4	23,845	Effectiveness of ASMQ FDC in reducing malaria transmission in the Juruá valley	Early detection of malaria and treatment with ASMQ FDC was feasible and efficacious, significantly reduced the incidence and morbidity of falciparum malaria[26]


Outcome and complication	No. (%)

Mortality	6 (14.2%)

30 day	2 (4.8%)

1 year	1 (2.4%)

5 years	2 (4.8%)

Complications

 Grade I	14 (33.3%)

 Grade II	2 (4.8%)

 Grade IIIa	4 (9.5%)

 Grade IIIb	2 (4.8%)

 Grade IV	3 (7.1%)

Massive intraoperative bleeding and edema.	2 (4.8%)

Wound infection	4 (9.5%)

New hemiparesis, sensory changes	4 (9.5%)

New cranial nerve palsy	7 (16.7%)

Deep vein thrombosis.	1 (2.4%)

Discharge location	42 (100%)

Home ± rehabilitation	24 (57.1%)

Rehabilitation center	14 (33.3%)

Convalescence hospital	2 (4.8%)

Hospital persist	2 (4.8%)

Karnofsky score at 1 year	(n = 38)

 > 70	23 (60.5%)

 < 70	15 (39.5%)

Karnofsky score at 5 years	(n = 34)

 > 70	20 (58.8%)

 < 70	14 (41.2%)


Ordered by socioeconomic variableb	Male	Female

Prevalencec	Times/dayd	Prevalencec	Times/dayd

Based on ranges. n = 24e

 Reason for extreme rates	1.06	1.26	1.26	6.00

 Difference of extreme rates	4.53	0.11	17.16	0.45

 Prevalence attributable to population	−3.44	−0.13	1.69	−0.07

 Prevalence attributable to population (%)	−4.39	−44.00	2.49	45.28

Based on disparity or dispersion. n = 33

 Pearcy-Keppel	0.57	2.29	0.66	1.23

 Pearcy-Keppel (Adjusted A)	28.02	0.21	25.34	0.08

 Variance between groups (VEG)	60.14	0.02	105.35	0.01

 Variance between groups (VEGA)	0.77	0.05	1.55	0.05

Based on disproportionality and concentration. n = 24

 Gini	0.05	0.22	0.08	0.25

 Concentration	0.01	0.12	−0.01	−0.05

Based on regression models. n = 24

 Coefficient β	0.12	−0.00	0.24	0.00

 Coefficient of determination	0.00	0.00	0.02	0.11

 Inequality of slope	3.23	0.22	−3.16	−0.05

 Inequality of Pamuk or relative	0.04	0.73	0.05	0.28

 Inequality of Kunst and Mackenbach	1.04	1.53	1.05	1.33

 Dimensional inequality	3.23	0.49	1.04	1.29

Based on the concept of entropy. n = 33

 Kullback-Liebler (Z)	0.01	0.09	0.01	0.11

 Hoover or dissimilitudes (Z)	0.04	0.15	0.06	0.17

 Theil (Z)	0.01	0.08	0.01	0.11


Pollutant	Concentration	Averaging period	Permitted exceedences each year

Cuprum [μ/m3]	0,6 μg/m3	1 year	n/a

PM10	40 μg/m3	1 year	n/a

Lead (Pb)	0,35 μg/m3	1 year	n/a


Publication	Zona pellucida breach	Embryonic stage	No of ET	Pregnancies conceived	Intervention	Outcome

ICSI	Assisted hatching	Embryo biopsy

Salat-Baroux et al., 1994	No	No	No	Cleavage	4	MCTA triplets	Reduction	DCDA miscarriage

DCDA twins

Belaisch-Allart et al., 1995	No	No	No	Cleavage	3	MCTA triplets	Nil	Delivery ?weeks

Yakin et al., 2001	Yes	No	No	Blastocyst	3	MCTA triplets	Reduction	DCDA delivery 36 weeks

DCDA twins

Ghulmiyyah et al., 2003	Yes	Yes	No	Blastocyst	2	MCTA triplets	Nil	CS at week 31

Ulug et al., 2004	Yes	Yes	No	Cleavage	3	MCTA triplets	Reduction	Singleton CS at week 38

Singleton

Yes	Yes	No	Cleavage	3	MCTA triplets	Nil	CS at week 34

Unger et al., 2004	Yes	No	No	Blastocyst	2	MCTA triplets	Reduction	Ongoing MCDA pregnancy 22 weeks

MCDA twins

Zikopoulos et al., 2004	Yes	No	No	Blastocyst	2	MCTA triplets	Reduction	Ongoing MCDA pregnancy 20 weeks

MCDA twins

Risquez et al., 2004	Yes	Yes	No	Cleavage	1	MCTA triplets	Nil	Ongoing pregnancy

16 weeks

Jain et al., 2004	No	No	No	Blastocyst	2	MCTA triplets	Nil	Ongoing pregnancy 7 weeks

Henne et al., 2005	No	No	No	Blastocyst	2	MCTA triplets	Termination

Yanaihara et al., 2007	No	No	No	Blastocyst	1	MCTA triplets	Termination

Lee et al., 2008	Yes	No	No	Blastocyst	1	MCTA triplets	Nil	CS at 33 weeks

Faraj et al., 2008	No	No	No	Blastocyst	1	MCTA triplets	Nil	CS at 32 weeks

Pantos et al., 2004	Yes	Yes	No	Day 4	3	MCTA triplets	Reduction	Singleton CS at 38 weeks

singleton

Haimov-Kochman et al., 2009	Yes	No	Yes	Day 4	3	MCTA triplets	Reduction	Singleton delivery at 38 weeks

singleton

Liu et al., 2010	No	No	No	Cleavage	2	MCQA	Nil	Miscarriage

Gurunath et al., 2015	No	No	No	Blastocyst	2	MCTA	Termination

Saravelos et al., 2015	Yes	No	Yes	Day 4	1	MCQA	Reduction	MCDA CS at 35 + 6 weeks

No	No	No	Blastocyst	1	MCTA	Reduction	Ongoing MCDA pregnancy


Location and day	Central station	Adjacent to patient

John Radcliffe Hospital Adult ICU weekday	58.4 dB	59.7 dB

John Radcliffe Hospital Adult ICU weekend	59.1 dB	59.5 dB

Royal Berkshire Hospital ICU weekday	58.7 dB	59.9 dB

Royal Berkshire Hospital ICU weekend	57.7 dB	58.5 dB

Wycombe General Hospital ICU weekday	52.4 dB	55.4 dB

Wycombe General Hospital ICU weekend	51.3 dB	54.1 dB

John Radcliffe Neurosciences ICU weekday	58.0 dB	58.8 dB

Churchill Hospital Adult ICU weekend	55.7 dB	55.4 dB


Gene ID	Description	Lineagea	dN/dS

			A	B	C	D	E

YDR197W	Mitochondrial translational activator of the COB mRNA	B	0.078	1.472	0.092	0.088	0.131

YER174C	Hydroperoxide and superoxide- radical responsive glutathione- dependent oxidoreductase	B	0.086	1.243	0.033	0.102	0.044

YFR041C	telomere maintenance	B	0.132	1.138	0.054	0.111	0.071

YGL119W	Protein required for ubiquinone (coenzyme Q) biosynthesis and for respiratory growth	B	0.045	4.607	0.044	0.073	0.078

YMR006C	glycerophospholipid metabolism	C	0.060	0.036	2.788	0.060	0.052

YPL248C	galactose metabolism; DNA- dependent regulation of transcription	C	0.175	0.240	1.078	0.145	0.170


Code	Before wetting	After wetting	Increased by

CH	220 μm	410 μm	46.34%

MCG	225 μm	310 μm	27.42%

F	240 μm	440 μm	45.45%

MF	300 μm	380 μm	21.05%


	Child demographics	Maternal psychopathology

Maternal Abuse Group	Age, M ± SD	Sex, % female	PTSD, M ± SD	Depression, M ± SD

Physical Childhood Abuse

 Low (n = 22)	8.9 ± 2.0	54.5	11.5 ± 11.0	17.3 ± 10.0

 High (n = 11)	10.7 ± 2.0*	45.5	22.3 ± 13.9*	28.5 ± 14.7*

Emotional Childhood Abuse

 Low (n = 24)	8.9 ± 2.1	54.2	11.9 ± 10.7	16.7 ± 9.7

 High (n = 9)	11.1 ± 1.4*	44.4	23.7 ± 15.0*	32.2 ± 13.6**

Sexual Childhood Abuse

 Low (n = 17)	8.6 ± 2.2	52.9	7.7 ± 7.9	14.8 ± 8.5

 High (n = 16)	10.4 ± 1.8*	50.0	22.7 ± 12.8**	27.7 ± 13.3**


 	Enthalpy of desolvation, ΔdesolvH (kJ mol−1) from DSC	Enthalpy of desolvation, ΔdesolvH (kJ mol−1) calculated from equation 4

Atorvastatin (ATC)	-

Solvate- I (ATC + 0.5 Isopropyl alcohol)	24.20	25.93

Solvate- II (ATC + THF)	51.47	57.17

Solvate- III (ATC + Ethanol)	44.69	34.39

Solvate- IV (ATC + 0.5 t-butanol)	78.85	78.31

Solvate- V (ATC + methanol)	26.27	26.70

Solvate-VI (ATC + 1 Acetone +0.5 Ethanol)	56.74	52.01

Solvate-VII (ATC + 0.5 Ethanol + Water)	104.64	103.96

Solvate- VIII (ATC + 1- butanol)	28.56	31.81


Behavioral trait

Time spent in predator channel (proportion)	0.44 ± 0.01n = 11

Direct approaches toward predator (proportion)	0.32 ± 0.03n = 11

Startle responses	0.52 ± 0.06n = 11

Number of freezes	0.99 ± 0.15n = 11

Relative swimming activity	0.17 ± 0.01n = 11


Analyte	FNa	FP

Original result (total)	Discrepant investigation outcomeb	Original result (total)	Discrepant investigation outcome

RP2 confirmed (TN)	RP2 unconfirmed (FN)	RP2 confirmed (TP)	RP2 unconfirmed (FP)

Viruses

Adenovirus	4	1	3	48	40	8

Coronavirus 229E	1	1	0	5	0	5

Coronavirus HKU1	0			12	3	9

Coronavirus NL63	0			10	3	7

Coronavirus OC43	8	2	6c	5	2	3

Human metapneumovirus	2	2	0	8	6	2

Human rhinovirus/enterovirus	11	6	5	77	33	44

Influenza virus A	0			0

H1	0			0

H1-2009	0			0

H3	0			0

Influenza virus B	0			2	2	0

Middle East respiratory syndrome coronavirus (MERS-CoV)	0			0

Parainfluenza virus 1	0			1	0	1

Parainfluenza virus 2	1	1	0	8	5	3

Parainfluenza virus 3	2	0	2	10	4	6

Parainfluenza virus 4	0			7	1	6

Respiratory syncytial virus	1	1	0	24	8	16

Bacteria

Bordetella parapertussis (IS1001)	1	0	1	0

Bordetella pertussis (ptxP)	1	0	1	1	1	0

Chlamydia pneumoniae	0			1	1	0

Mycoplasma pneumoniae	1	0	1	5	5	0

Total	33	14	19	224	114	110


	Survivors(n = 45)	Nonsurvivors(n = 43)

Age (mean ± SD)	42 (35-50)	38 (29-46)

Male gender (%)	36 (80%)	31 (72%)

Location before ICU (ward, %)	24 (53%)	29 (67%)

Performance status 3 or 4	1 (0-2)	2 (1-3)

CD4 count <50 mm3 (%)	20 (44%)	21 (49%)

Length of time from AIDS diagnosis	39 (2-92)	50 (2-85)

Recent (<3 months) AIDS diagnosis	13 (29%)	13 (30%)

HAART use	20 (44%)	20 (46%)

SAPS II expanded (points)	44 (37-54)	54 (46-67)b

SOFA D1 (points)	4 (1-7)	7 (4-10)b

Mechanical ventilation	17 (38%)	36 (84%)b

Use of vasopressors on day 1	6 (13%)	15 (30%)a

Renal support	3 (7%)	13 (30%)b

Severe sepsis/septic shock (%)	15 (33%)	29 (67%)b

ICU length of stay (days)	9 (5-17)	10 (4-14)

Hospital length of stay (days)	24 (12-58)	15 (10-24)a


Characteristics	Correlation coefficient (r)	P value

AA	SS	AA	SS

Age 	−0.752	−0.744	0.000	0.000

BMI	0.120	0.386	0.241	0.000

Subischial leg length	−0.922	−0.919	0.000	 0.000

Sitting height	−0.728	−0.670	0.000	0.000

Weight	−0.565	−0.700	0.000	0.000


Variable	β	SE	Ventricular septal defects (yes vs. no)	P value

Odds ratio	95% confidence interval

NBL	−0.37	0.12	0.69	0.55 to 0.87	0.001

UA PI	 2.09	0.32	8.10	4.31 to 15.21	<0.0001

MCA PI	−1.37	0.38	0.25	0.12 to 0.54	<0.0001


 	RSV group A	 	RSV group B

 	Global	Dadaab	Global	Dadaab

Period (years)	2006-11	2007-11	2006-11	2007-11

Total Sequences@	649	182	504	108

Overall % Genetic distance	6.9	1.4	4.7	2.4

Sequences Unique (%)*	338 (52.1)	39 (21.4)	361(71.6)	24 (22.2)

Number of genotypes identified	2	2	4	1


 	n	Mean	Std. Deviation

FRACTURE STRENGTH	80	1016.6670	171.58485


Spot no.	Identity	MW (Da)	GenBank acc. no.	FC

1	Ser/Thr-specific protein phosphatase 2A A regulatory subunit β isoform (Medicago sativa subsp.×varia)	65161.6	AAG29594	0.647

2	Pyruvate kinase (Lactuca sativa)	56174.9	ABS87384	0.481

3	Branched-chain amino acid aminotransferase, putative (Ricinus communis)	45159.9	XP_002530599	0.541

4	Glucose-6-phosphate isomerase (Zea mays)	68403.5	NP_001147983	1.837

5	Actin (Phaseolus acutifolius)	33121.3	AAZ95077	2.277

6	Dehydrin (Phaseolus vulgaris)	22955.6	AAB00554	2.048

7	Dehydrin (Phaseolus vulgaris)	22955.6	AAB00554	1.846

8	Lactoylglutathione lyase, putative/glyoxalase I, putative (Arabidopsis thaliana)	20830.4	NP_001030996	2.414

9	Dehydrin (Phaseolus vulgaris)	22955.6	AAB00554	2.438

10	Dehydrin (Phaseolus vulgaris)	22955.6	AAB00554	1.625


	CS-cineCMR	3D-HR-CMR(ref)	Diff	Diff [%]

	Volume [ml]	Volume [ml]	Volume [ml]

Patient 1	62.5	59.0	3.5	5.7 %

Patient 2	61.5	71.0	−9.5	−14.3 %

Patient 3	395.0	397.0	−2.0	−0.5 %


Study sites	Sampling units (classes of listed educational institutions below, wards of Village Development Committee (VDCa ))	Sampling unit population	Sample size (i.e. number of respondents)	Sample size (%)

Bachhayauli	Class 12, Jhuwani Higher Secondary School, Bachhayauli 09, Chitwan	33 (10 students, 23 teachers)b	25 (10 students, 15 teachers)	76

Ward number 3, Bachhayauli VDCa, Chitwan	148 household headsc	25 (household heads)	17

Baghauda	Bachelor’s degree of Business Studies, 1st year, Madi Multiple Campus, Tribhuvan University, Baghauda 03, Chitwan	44 (24 students, 20 teachers)b	25 (10 students, 15 teachers)	57

Ward number 5, Baghauda VDCa, Chitwan	87 household headsc	25 (household heads)	29

Meghauli	Class 11 and 12, Janaki Higher Secondary School, Telauli, Meghauli 05, Chitwan	60 (28 students, 32 teachers)b	25 (10 students, 15 teachers)	42

Ward number 6, Meghauli VDCa, Chitwan	43 household headsc	25 (household heads)	58

	Total	415	150 (30 students, 45 teachers, 75 villagers)	36


First examiner	Hand	Thyroid 	Eye lens	Chest	No. of Film	Exposure time (min)	X-ray tube location

Present study	27.0	5.0	3.0	6.0	2.5	2.4	Overcouch

Buls et al [14]	0.64	0.45	0.55	nd	4	6.0	Overcouch

Naidu et al. [9]*	NR	0.2	0.04	NR	4.6	5.9	Overcouch

Sulieman et al. [3] 	27.2	5.4	3.8	6.2	2.6	2.9	Overcouch

Oztas et al. [10]	20.0	2.0	82.0	NR	1.7	5.7	undercouch


Population n	Age (years)/avg ± SD range	Mass (kg)/Avg ± SD range	Stature (m)/Avg ± SDr ange	BMI/Avg ± SD range

10(f = 3, m = 7)	35.8 ± 8.822–53	53.6 ± 10.444–73	1.60 ± 0.091.45–1.75	20.7 ± 3.116.4–25.9


Funcats	Number of genes assigned an InterAct class	Number of InterAct class 0000 genes	p-value

All funcats	3,447	1,089	-

Metabolism	496	120	6.0 × 10-4

Protein synthesis	218	55	2.6 × 10-2

Energy	125	21	1.34 × 10-4


Characteristics	No. of errors	%

Gender

Male	860	64.5

Female	473	35.5

Total	1333	100

Age group

Less than 1 year	593	44.5

1-3 years	249	18.7

4-6 years	167	12.5

7-9 years	43	3.2

10-12 years	281	21.1

Total	1333	100

Administration route

Intravenous	669	50.2

Oral	342	25.7

Inhalation	222	16.6

Topical	60	4.5

Subcutaneous	24	1.8

Intramuscular	16	1.2

Total	1333	100

Location

PICU	452	33.9

Pediatric wards	881	66.1

Total	1333	100


Drugs:	n	%

Adefovir	1	1.9

Boceprevir	1	1.9

Entecavir	9	17.3

Interferon	4	7.7

Pegylated interferon	9	17.3

Lamivudine	4	7.7

Ribavirin	13	25.0

Telapravir	1	1.9

Tenofovir	10	19.2

Total	52	100


Variables	Entire sample (100%)	Multiple sclerosis§ (46%)	Depressive disorders (32%)	Psychotic and other disorders (22%)*	Statistics (Pearson’s χ2 or ANOVA)

Gender, %	 	 	 	 	p < .0001

Women	68	78	66	56

Men	32	22	34	44

Age, years (Mean, standard deviation)	41 ± 13	43 ± 11	41 ± 14	38 ± 13	F = 5.2; p = .006

Family status, %	 	 	 	 	p < .0001

Married	58	56	50	67

With partner, not married	22	17	34	21

Divorced	11	19	0	0

Single	10	8	16	12

Educational level, %	 	 	 	 	p = .007

Through Grade 9	24	22	26	26

Through Grade 10	33	33	37	31

High school diploma	38	36	37	41

Other	5	9	0	1

Spiritual/religious self-categorization, %	 	 	 	 	n.s.

R + S + (religious and spiritual)	15	12	16	18

R + S- (religious, not spiritual)	21	19	24	21

R-S + (not religious but spiritual)	15	16	14	14

R-S- (neither religious nor spiritual)	50	54	47	46

Engagement in spiritual activities (0–100)**

Existential practices	54 ± 25	43 ± 11	60 ± 23	62 ± 22	F = 23.2; p < .0001

Humanistic practices	65 ± 19	65 ± 19	66 ± 16	65 ± 20	F = 0.1; n.s.

Religious practices	26 ± 24	22 ± 24	31 ± 25	27 ± 23	F = 5.1; p = .007

Spiritual (MB) practices	19 ± 22	21 ± 24	15 ± 17	19 ± 21	F = 2.6; n.s.

Gratitude/Awe	42 ± 24	44 ± 22	38 ± 25	43 ± 25	F = 2.2; n.s.

Life satisfaction Sum Score (BMLSS-10) (0-100)	54.6 ± 22.3	69.1 ± 17.1	42.5 ± 15.6	42.5 ± 20.7	F = 123.1; p < .0001

Life Satisfaction Subdimensions (0–6)

Family life	3.62 ± 1.83	4.60 ± 1.45	2.83 ± 1.55	2.84 ± 1.84	F = 66.0; p < .0001

Friendships	3.70 ± 1.73	4.49 ± 1.43	3.03 ± 1.64	3.06 ± 1.73	F = 46.7; p < .0001

Work situation	2.82 ± 1.96	3.69 ± 1.72	2.30 ± 1.75	2.18 ± 1.98	F = 28.2; p < .0001

Myself	2.81 ± 1.80	4.00 ± 1.40	1.82 ± 1.44	1.88 ± 1.53	F = 121.5; p < .0001

Where I live	4.01 ± 1.64	4.55 ± 1.42	3.50 ± 1.61	3.62 ± 1.71	F = 22.1; p < .0001

Life in general	3.32 ± 1.69	4.39 ± 1.20	2.21 ± 1.37	2.32 ± 1.66	F = 142.6; p < .0001

Financial situation	3.24 ± 1.83	3.93 ± 1.55	2.82 ± 1.76	2.59 ± 1.92	F = 29.6 ; p < .0001

Future prospects	2.92 ± 1.60	3.64 ± 1.29	2.22 ± 1.49	2.43 ± 1.66	F = 43.5; p < .0001

Health situation	2.45 ± 1.62	3.20 ± 1.49	1.89 ± 1.39	1.77 ± 1.47	F = 50.3; p < .0001

Abilities to deal withDaily life activities	3.07 ± 1.62	4.03 ± 1.33	2.29 ± 1.26	2.24 ± 1.47	F = 94.8; p < .0001


 	 	 	 	 	IOP	Visual acuity

Patient code	Gender	Age Dx	Diagnosis	Gly326Ser	RE	LE	RE	LE	Surgical procedure

G62	Male	59/65	OHT/POAG	yes	30	30	20/40	20/40	Trabeculectomy LE

01A	Female	65	Blind by POAG	yes	ptosis	20	HM	HM	-

03A	Female	63	OHT with tendency to angle closure	yes	26	20	20/30	20/30	Iridotomy

24A	Male	72	Advanced POAG	yes	26	26	HM	20/40	-

05A	Male	75	Pseudo exfoliation Glaucoma	no	25	17	-	20/40	Trabeculectomy, cataract surgery

08A	Male	76	POAG	no	22	23	20/50	20/40	Trabaculoplasty


Parameter	Correct

Study 1, No. (%)	Study, No. (%)	p

Registration of insertion date	337 (42.3)	339 (50.1)	0.003

Registration of daily surveillance	779 (97.7)	660 (98.2)	0.52

Registration of dressing change date	322 (41.2)	328 (49.1)	0.003

Registration of set replacement date	74 (45.4)	65 (43.3)	0.71

Use of connectors (split-septum) in all hubs	660 (83.7)	615 (92.2)	<0.001


Characteristics	LGSOCNo. of patients (%)	HGSOCNo. of patients (%)	p values

All cases	25	55

Mean Age, years (± SEM)	49.8 ± 3.0	56.8 ± 1.5	0.03

Type of primary surgery

 Cytoreduction	25	55	–

Residual tumor after primary surgery (cm)

 0	22	36	0.06#

 < 1	3	14

 > 1	0	5

FIGO Stage

 I/II	10 (40)	8 (15)	0.01

 III/IV	15 (60)	47 (85)

Primary chemotherapy

 None	3 (12)	1 (1.8)	0.08§

 Platinum/paclitaxel	17 (68.0)	48 (87.3)

 Platinum-based	4 (16.0)	5 (9.1)

 Other	1 (4)	1 (1.8)


	p-Nephrin	Nck (with p-Nephrin)	Nck (with p-TIR)	N-WASP

Null hypothesis	Single Exp.	Single Exp.	Single Exp.	Single Exp.

Alternate hypothesis	Double Exp.	Double Exp.	Double Exp.	Double Exp.

p value	<0.0001	<0.0001	<0.0001	<0.0001

Conclusion (alpha = 0.05)	Reject null hypo.	Reject null hypo.	Reject null hypo.	Reject null hypo.

Preferred model	Double Exp.	Double Exp.	Double Exp.	Double Exp.

F (DFn, DFd)	64.16 (2282)	47.33 (2635)	46.72 (2379)	48.64 (2379)


	Talairach coordinates

	Hemisphere	BA	x	y	z	Volume (mm3)	Mean t

REGION OF ACTIVATION

Medial frontal gyrus	Left/Right	6/8	5	18	43	2590	5.40

Anterior insula	Right	13	41	18	5	4015	5.67

Anterior insula	Left	13	−30	18	5	1153	5.13

Dorsolateral prefrontal gyrus	Right	9/10	38	42	27	888	4.94

Precentral gyurs	Right	9	43	26	34	1262	5.10

Middle frontal gyrus	Right	9	45	12	36	2422	5.18

Middle frontal gyrus	Left	9	−41	29	37	67	4.72

Middle temporal gyrus	Right	21	56	−25	−5	191	4.86

Inferior parietal lobe	Right	40	48	−44	37	2744	5.42

Inferior parietal lobe	Left	40	−46	−37	41	595	5.05

Precuneus	Right	7	10	−68	39	299	5.01

Nucleus caudatus	Right		13	8	12	224	5.38

Thalamus	Right		10	−12	10	113	4.82

Thalamus	Left		−7	−16	9	131	5.01

REGION OF DEACTIVATION

Anterior cingulate gyrus	Left/Right	32	−2	36	−3	3226	−5.23

Superior frontal gyrus	Left	8	−17	26	45	315	−4.90

Posterior cingulate gyrus	Left/Right	30	−2	−53	20	560	−5.21


	B. subtilis	S. aureus	A. niger	S. cerevisiae

(a) Activity per full feces sample

Feces producer (FP)	P = 0.440	P = 0.098	P = 0.005	P <0.0001

Mother-offspring interactions (MO)	P = 0.808	P = 0.104	P = 0.342	P = 0.051

FP : MO	P = 0.553	P = 0.934	P = 0.068	P = 0.215

(b) Activity per mg of feces

Feces producer (FP)	P <0.0001	P = 0.008	P = 0.095	P = 0.080

Mother-offspring interactions (MO)	P = 0.813	P = 0.575	P = 0.052	P = 0.078

FP : MO	P = 0.812	P = 0.731	P = 0.037	P = 0.089


 	Dictionary	Token features	Linguistic features	Semantic features

 	 	 	 	TUI	CUI

Baseline I	 	 	 	X

Baseline II	X

Experiment I	X	X	X

Experiment II	X	X	X	X

Experiment III	X	X	X	 	X


First author, [Ref] year, country	Study design	No. of case/controls (cohort)	Exposure category	Risk estimates (95% CI)	Adjustment for confounders

Age	BMI	Parity	HRT	OC use

Neill et al. [15], 2013, Australia	Population-based case-control	1398/740	Ever vs. Never≥ 2 week vs. Never	1.19 (0.86−1.65)0.77 (0.41−1.45)	√	√	√	√	√

Setiawan et al. [16], 2012, USA	Cohort	620/64000	Ever vs. Never≥ 6 years vs. Never	0.96 (0.81−1.13)0.80 (0.61−1.06)	√	√	√	√	√

Walter et al. [17], 2011, USA*	Cohort	214/32059	Ever vs. Never≥4 d/week and ≥ 4 years vs. Never	1.05 (0.72−1.54)0.99 (0.48−2.01)	√	√	×	√	×

Bodelon et al. [18], 2009, USA	Population-based case-control	410/356	Ever vs. Never≥ 10 years vs. Never	1.11 (0.70−1.77)1.80 (0.91−3.56)	√	√	×	√	×

Viswanathan et al. [19], 2008, USA*	Cohort	747/82971	Ever vs. Never≥ 6–7 d/weeks vs. Never	1.11 (0.70−1.77)0.86 (0.57−1.30)	×	√	√	√	√

Moysich et al. [20], 2005, USA	Hospital-based case-control	427/427	Ever vs. Never≥ 10 years vs. Never	0.96 (0.60−1.54)0.49 (0.15−1.60)	√	√	√	×	×

Friis et al. [21], 2002, Denmark	Cohort	58/26272	Ever vs. Never	1.10 (0.80−1.40)	×	×	×	×	×


Resistance pattern	N

Double drugs

 MNZ + LVX	12 (28.6)

 MNZ + CAM	3 (7.1)

Triple drugs

 CAM + MNZ + LVX	5 (11.9)


Gene name	AGI code	Forward primer sequence	Reverse primer sequence

ACL5	At5g19530	ACCGTTAACCAGCGATGCTTT	CCGTTAACTCTCTCTTTGATTC

XTH3	At3g25050	GTGTTTTTGTAGTAACGTTATGG	GGTTGGATTGAACCAAAGCAA

VND6	At5g62380	ATGGAAAGTCTCGCACACAT	CTCTTCCACATAACTCTTGG

VND7	At1g71930	CGATGCATCAATATGGCAAC	AGGGAAGCATCCAAGAGAAT

CNA	At1g52150	GGTATTTGCTGATTCATGAGC	ATGGTTTACACTTGACAGAGC

ATHB8	At4g32880	AGCGTTTCAGCTAGCTTTTGAG	CAGTTGAGGAACATGAAGCAGA

MP/ARF5	At1g19850	GATGATCCATGGGAAGAGTT	TAAGATCGTTAATGCCTGCG

TMO5L1	At1g68810	CACCACCAAAACGGATAAAG	CGTTTTGAGACGCATAGCTT

PIN1	At1g73590	CTTAGCACTGCGGTGATATT	TTGCTGAGCTCCTACTTAAG

PIN6	At1g77110	CTATCGTACAGGCTGCTCTA	CTCCTCAAGAACAACTCTTA

YUC2	At4g13260	ATGTGGCTAAAGGGAGTGAA	AACTTGCCAAATCGAAACCC

IRT1	At4g19690	GTCTAATCACTCTAGCCATTGA	TGTATACTCAGCCTGGAGGA

PXY/TDR	At5g61480	CGGTTACATTGCACCAGAAT	GCTTGTACACAACAACGCAA

SAC51	At5g64340	AATTGCCAGGCTGAGTACTT	GACCGACCTACTATATCCTT

ACT8	At1g49240	GTGAGCCAGATCTTCATTCGTC	TCTCTTGCTCGTAGTCGACAG


	Culprit plaque	Totals

	Acute rupture	Healing rupture	Stable plaque

N	51	5	16	72

Age, years ± SD	52 ± 11	52 ± 10	48 ± 8	51 ± 11

Men: women	47:4	5:0	14:2	66:6

White:Black	38:13	3:2	12:4	53:19

Heart weight, g ± SD	504 ± 127	605 ± 125	466 ± 87	511 ± 134

Diabetic	9	0	1	10

Hypertensive	13	4	5	22

Hypercholesterolemic	25	3	9	37

Smokers	26	3	7	36

Number of plaques studied	100*	7	28	135

 Acute ruptures	61	0	0	61

 Healing ruptures	8	0	0	15

 Thin cap FA	20	7	11	31

 FA	11	0	17	28


Integration Block	Frame Rate (frames per second)

L&K C 9 × 9 Integration Block	0.3

L&K C 9 × 9 SIB	0.9

L&K C 9 × 9 SIB	3.6

L&K ASM 9 × 9 SIB and propagation	11.9

L&K C 5 × 5 Integration Block	1.3

L&K C 5 × 5 SIB	3.3

L&K C 5 × 5 SIB and propagation	8.9

L&K ASM 5 × 5 SIB and propagation	28.8


Characteristics	N	%

Median age, years (range)	62.1 (21.1–79.7)

Male / Female	65/44	59.6/40.4

Median Karnofsky performance status (range)	70 (30–90)

Extent of surgery

- Complete resection	82

- Partial resection	27	24.8

Radiotherapy	84	77.1

Median OS, months (range)	13.2 (1.5–141.4)

Median PFS, months (range)	7.9 (0.9–132.4)


A) Factors differentiating those who do / do not recover during follow up	Odds ratio (95% CI)	p-value	Interpretation

Ethnicity(Caucasian vs non-Caucasian)	14.19 (2.52, 122.63)	0.007	Non-Caucasians – less likely to recover from proteinuria

eGFR	1.04 (1.02, 1.08)	0.007	Low eGFR at proteinuria onset - less likely to recover

Azathioprine use	0.093 (0.01, 0.78)	0.044	Use of Azathioprine at proteinuria onset – less likely to recover

Haematological involvement	0.13 (0.03, 0.53)	0.007	Haematological involvement – less likely to recover

Cardiorespiratory involvement	11.22 (1.57, 107.54)	0.022	Cardiorespiratory involvement - more likely to recover

B) Factors influencing time to recovery from proteinuria	HR (95% CI)	p-value

Age (years)	1.38 (1.1, 1.8)	0.007	Younger patients - less likely to recover

eGFR	1.0 (1.0, 1.1)	0.036	Lower eGFR - less likely to recover

Haematological involvement	0.3 (0.1, 0.8)	0.016	Haematological involvement - less likely to recover


	Original EpiPen	New-look EpiPen	Anapen

Step 1: Remove safety caps	Form a fist around EpiPen and remove gray safety cap	Form a fist around EpiPen and pull off blue safety release	1. Pull off black needle shield

2. Pull off gray safety cap from red button

Step 2: Place against thigh	Place black end against outer mid thigh (with or without clothing)	Place orange end against outer mid thigh (with or without clothing)	Place needle end firmly against outer mid-thigh (with or without clothing)

Step 3: Push and inject	Push down hard until a click is heard or felt and hold in place for 10 seconds	Push down hard until a click is heard or felt and hold in place for 10 seconds	Press red button so it clicks and hold in place for 10 seconds.

Step 4: Remove and massage site	Remove EpiPen and do not touch needle. Massage injection site for 10 seconds	Remove EpiPen. Massage injection site for 10 seconds.	Remove Anapen and do not touch needle. Massage injection site for 10 seconds.


Shared by:	C. graminicola	Shared by:	C. sublineola

OrthoMCL	RBH	OrthoMCL	RBH

CgramCsubChigg	9281	9264	Cgram:Csub:Chigg	9323	9252

Cgram:Csub	1015	1018	Csub:Cgram	1036	1057

Cgram:Chiggs	473	560	Csub:Chiggs	333	500

Cgram only	134	1164	Csub only	456	2502

Not Characterized	1103	0	Not Characterized	2163	0

Total	12006	12006	Total	13311	13311


Pathways	Infection related	Pathways in

 	pathways	cancer

Gene No.	1082	326

Overlap between pathways in cancer and infection related pathways	169

Hum-Mtb targeted Human proteins Overlap with HP-PPI targeted human proteins	204	29

Overlap of the three datasets	20


Space group	P21

Unit cell dimensions

a (Å)	42.2

b (Å)	64.3

c (Å)	48.6

β (°)	102.1

Number of molecules in the unit cell	2

Resolution range (Å)	36.0 - 1.2

The range of the highest shell	1.24 - 1.20

Total number of measured reflections	727277

Number of unique reflections	62459

Rsym (%)	5.0(22.1)

I/σ(I)	17.8(3.6)

Completeness of data (%)	98.5(87.1)

Rcryst (%)	15.8

Rfree (%) 5% of reflections	18.6

Protein atoms	2101

Water oxygen atoms	434

Phosphate ion atoms (1)	5

Atoms from PEG	40

R.m.s.d in bond lengths (Å)	0.008

R.m.s.d in bond angles (°)	1.2

R.m.s.d in torsion angles (°)	16.8

B-factors (Å2)

B-factor from Wilson plot (Å2)	12.3

Mean B-factor for main chain atoms (Å2)	11.2

Mean B-factor for side chain and water atoms (Å2)	19.2

Mean B-factor for all atoms(Å2)	15.8

Ramachandran's φ, ψ map

Residues in the most favoured regions (%)	90.4

Residues in the additionally allowed regions (%)	9.3

Residues in the generously allowed regions (%)	0.3

PDB ID	3MU7


<underline>Month</underline>	<underline>Dietary recall since birth</underline>	<underline>24-hour dietary recall</underline>	<underline>Difference</underline>	<underline>Difference</underline>

	EBF	PBF	EBF	PBF	EBF	PBF

1	45	68	96	98	51	30

2	12	46	90	92	78	46

3	7	30	81	84	74	54

4	3	14	70	73	67	59

5	1	6	62	65	61	59

6	0	3	52	55	52	52

7		0	42	45		45

8			33	35

9			23	25

10			12	13

11			5	6

12			0	0


Outcome parameter	Instrument	Hypotheses	To be filled out by

Psychosocial functioning (inclusion criteria)	Global assessment of functioning[14]	II	Psychiatrist

Psychopathology	Brief Psychiatric Rating Scale (BPRS)[15]	II	Psychiatrist

Patient

Life satisfaction	11 point scale from the German Socioeconomic Panel[16]	II	Patient

Functional impairment	WHO-Disability Assessment Scale (WHO-DAS II)[17]	II	Patient

Substance misuse	Alcohol Use und Drug Use Scale (AUS, DUS)[18]	II	Patient

Medical adherence	Medical Adherence Rating Scale (MARS)[19]	II	Patient

Patient satisfaction with medical care1	Patient Assessment of Chronic Care (PACIC)[20]	III	Patient

Service use1,2	Client Sociodemographic and Service Receipt Inventory (CSSRI)[21]	I+IV	Practice assistant


Groups	High fat diet a (%)	Others	Dietary energy contributions a(Kcal/100 g pellet)

Normal	0	100% normal rat pellet	335

High fat diet	50	50% normal rat pellet	548

50% Germinated brown rice	50	50% germinated brown rice	554

Low dose OE	100	100 mg/kg/day OE	554

High dose OE	100	200 mg/kg/day OE	554


Characteristic	Number (percentage)a

Age group (in years)

15 – 29	2137 (48.4)

30 – 44	1475 (33.4)

45 – 59	808 (18.3)

Marital status

Never married	1267 (28.7)

Currently married	2671 (60.5)

Widow or divorcee	482 (10.9)

Place of residence

Rural	1864 (42.2)

Urban	2556 (57.8)

Religion

Christians	3096 (70.0)

Muslims	755 (17.1)

Others	569 (12.9)

Level of education

No school	540 (12.2)

Primary	1573 (35.6)

Secondary/higher	2306 (52.2)

Wealth index

Low	1456 (32.9)

Middle	1463 (33.1)

High	1501 (34.0)

Number of lifetime sex partners

0 – 5	1937 (43.8)

6 – 95	2473 (56.0)

Age at first sexual intercourse

≤ 17 years	2192 (49.6)

> 17 years	2215 (50.1)


Test	True positive (sensitivity)	False negative (1 − sensitivity)	True negative (specificity)	False positive (1 − specificity)	Total

Criteria	HPHPA > 101.5 mmol/mol creatinine

Control	 	 	61 (98.4%)	1 (1.6%)	62

ASDs	45 (72.6%)	17 (27.4%)	 	 	62

Criteria	3HPA > 45.2 mmol/mol creatinine

Control	 	 	62 (100%)	0 (0%)	62

ASDs	18 (29%)	44 (71%)	 	 	62

Criteria	3HHA > 14.8 mmol/mol creatinine

Control	 	 	60 (96.8%)	2 (3.2%)	62

ASDs	21 (33.9%)	41 (66.1%)	 	 	62

Criteria	Prediction probability > 0.65 (based on the three metabolites)

Control	 	 	98.4%	1.6%

ASDs	90.3%	9.7%


No. components in analysis	Best component(s)	Accuracy

One	H2BK5ac at TSS	0.72

Two	H2BK5ac at TSS-1	0.74

H2BK5ac at TSS-2

Three	H2BK5ac at TSS-1	0.75

H2BK5ac at TSS-2


Materials	E. coli (G−)	S. aureus (G+)	S. enterica (G−)	M. luteus (G+)	P. multocida (G−)	Cytospora sp.	P. piricola	F. oxysporum f. sp. cucumebrium

C3-3-2-2 a	0.46	- b	0.46	-	0.46	0.46	0.94	-

hurgadacin	0.46	3.75	0.94	>3.75	0.46	>3.75	0.94	>3.75


Category	N animals	Mean (l milk)	Std

Top sixth	16	39.7	9.3

Worse sixth	16	−29.0	5.2

Top twelfth	8	47.2	8.1

Worse twelfth	8	−32.5	5.5


Inflammatory reaction signs	SDE group	IRDE group

SS	SLE	RA	Total

Conjunctival congestion ratio	32.2%a	69.3%	78.5%	63.1%	70.3%a

Conjunctival papillary hyperplasia ratio	27.5%b	52.4%	61.8%	50.8%	55.0%b

Conjunctival follicular hyperplasia ratio	16.3%c	36.8%	40.4%	39.2%	38.8%c

Secretion ratio	12.6%d	10.1%	13.6%	10.6%	11.4%d